



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/54	A1	(11) International Publication Number: WO 99/09063 (43) International Publication Date: 25 February 1999 (25.02.99)															
(21) International Application Number: PCT/IL98/00379 (22) International Filing Date: 13 August 1998 (13.08.98) (30) Priority Data: <table border="0" style="width: 100%;"> <tr> <td style="width: 30%;">121554</td> <td style="width: 40%;">14 August 1997 (14.08.97)</td> <td style="width: 30%;">IL</td> </tr> <tr> <td>121639</td> <td>27 August 1997 (27.08.97)</td> <td>IL</td> </tr> <tr> <td>121860</td> <td>29 September 1997 (29.09.97)</td> <td>IL</td> </tr> <tr> <td>122134</td> <td>6 November 1997 (06.11.97)</td> <td>IL</td> </tr> <tr> <td>125463</td> <td>22 July 1998 (22.07.98)</td> <td>IL</td> </tr> </table> (71) Applicant (for all designated States except US): YEDA RESEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; Weizmann Institute of Science, P.O. Box 95, 76100 Rehovot (IL). (72) Inventors; and (75) Inventors/Applicants (for US only): NOVICK, Daniela [IL/IL]; Hanassi Harishon 40, 76302 Rehovot (IL). DINARELLO, Charles [US/US]; 333 15th Street, Boulder, CO 80302 (US). RUBINSTEIN, Menachem [IL/IL]; 16 Hatomer Street, 54042 Givat Shmuel (IL). KIM, Soo, Hyun [KR/IL]; Hamaapil Street 4, 76348 Rehovot (IL). (74) Agent: EINAV, Henry; Inter-Lab Ltd., Science-based Industrial Park, Kiryat Weizmann, 76110 Ness-Ziona (IL).		121554	14 August 1997 (14.08.97)	IL	121639	27 August 1997 (27.08.97)	IL	121860	29 September 1997 (29.09.97)	IL	122134	6 November 1997 (06.11.97)	IL	125463	22 July 1998 (22.07.98)	IL	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
121554	14 August 1997 (14.08.97)	IL															
121639	27 August 1997 (27.08.97)	IL															
121860	29 September 1997 (29.09.97)	IL															
122134	6 November 1997 (06.11.97)	IL															
125463	22 July 1998 (22.07.98)	IL															
(54) Title: INTERLEUKIN-18 BINDING PROTEINS, THEIR PREPARATION AND USE (57) Abstract <p>Interleukin-18 binding proteins which are capable of binding IL-18 and/or modulating and/or blocking IL-18 activity are provided. Methods for their isolation and recombinant production, DNAs encoding them, DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided.</p>																	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERLEUKIN-18 BINDING PROTEINS,

THEIR PREPARATION AND USE

Field of the Invention

5 The present invention relates to interleukin-18 (IL-18) binding protein, hereinafter IL-18BP, capable of binding IL-18. More particularly, this invention relates to a soluble IL-18BP obtainable from body fluids, to soluble IL-18BPs obtainable by expression of suitable DNA vectors in host cells, to virus-encoded homologues of IL-18BP obtainable by expression of suitable DNA vectors in host cells, to vectors expressing the various IL-18BPs,
10 to vectors useful for expression of IL-18BP in humans and other mammals, to antibodies against IL-18BPs, to therapeutic use of said IL-18BPs by modulating and/or blocking IL-18 activity, to therapeutic use of said expression vectors in modulating and/or blocking IL-18 activity and to use of the antibodies.

Background of the Invention

15 In 1989, an endotoxin-induced serum activity that induced interferon- γ (IFN- γ) obtained from mouse spleen cells was described (27). This serum activity functioned not as a direct inducer of IFN- γ but rather as a co-stimulant together with IL-2 or mitogens. An attempt to purify the activity from post-endotoxin mouse serum revealed an apparently homogeneous 50-55 kDa protein (26). Since other cytokines can act as co-stimulants for
20 IFN- γ production, the failure of neutralizing antibodies to IL-1, IL-4, IL-5, IL-6, or TNF to neutralize the serum activity suggested it was a distinct factor. In 1995, the same scientists demonstrated that the endotoxin-induced co-stimulant for IFN- γ production was present in extracts of livers from mice preconditioned with *P. acnes* (31). In this model, the hepatic macrophage population (Kupffer cells) expand and in these mice, a low dose of bacterial
25 lipopolysaccharide (LPS), which in non-preconditioned mice is not lethal, becomes lethal. The factor, named IFN- γ -inducing factor (IGIF) and later designated interleukin-18 (IL-18), was purified to homogeneity from 1,200 grams of *P. acnes*-treated mouse livers. Degenerate oligonucleotides derived from amino acid sequences of purified IL-18 were used to clone a

murine IL-18 cDNA (31). IL-18 is an 18-19 kDa protein of 157 amino acids, which has no obvious similarities to any peptide in the databases. Messenger RNAs for IL-18 and interleukin-12 (IL-12) are readily detected in Kupffer cells and activated macrophages. Recombinant IL-18 induces IFN-gamma more potently than does IL-12, apparently through a
5 separate pathway (31). Similar to the endotoxin-induced serum activity, IL-18 does not induce IFN- γ by itself, but functions primarily as a co-stimulant with mitogens or IL-2. IL-18 enhances T cell proliferation, apparently through an IL-2-dependent pathway, and enhances Th1 cytokine production *in vitro* and exhibits synergism when combined with IL-12 in terms of enhanced IFN- γ production (24).

10 Neutralizing antibodies to mouse IL-18 were shown to prevent the lethality of low-dose LPS in *P. acnes* pre-conditioned mice. Others had reported the importance of IFN- γ as a mediator of LPS lethality in pre-conditioned mice. For example, neutralizing anti-IFN- γ antibodies protected mice against Schwartzman-like shock (16), and galactosamine-treated mice deficient in the IFN- γ receptor were resistant to LPS-induced death (7). Hence, it was
15 not unexpected that neutralizing antibodies to murine IL-18 protected *P. acnes*-preconditioned mice against lethal LPS (31). Anti-murine IL-18 treatment also protected surviving mice against severe hepatic cytotoxicity.

After the murine form was cloned, the human cDNA sequence for IL-18 was reported in 1996 (38). Recombinant human IL-18 exhibits natural IL-18 activity (38). Human
20 recombinant IL-18 is without direct IFN- γ -inducing activity on human T-cells, but acts as a co-stimulant for production of IFN- γ and other T-helper cell-1 (Th1) cytokines (38). To date, IL-18 is thought of primarily as a co-stimulant for Th1 cytokine production (IFN- γ , IL-2 and granulocyte-macrophage colony stimulating factor) (20) and also as a co-stimulant for FAS ligand-mediated cytotoxicity of murine natural killer cell clones (37).

25 By cloning IL-18 from affected tissues and studying IL-18 gene expression, a close association of this cytokine with an autoimmune disease was found. The non-obese diabetic (NOD) mouse spontaneously develops autoimmune insulinitis and diabetes, which can be accelerated and synchronized by a single injection of cyclophosphamide. IL-18 mRNA was demonstrated by reverse transcriptase PCR in NOD mouse pancreas during early stages of
30 insulinitis. Levels of IL-18 mRNA increased rapidly after cyclophosphamide treatment and

preceded a rise in IFN- γ mRNA, and subsequently diabetes. Interestingly, these kinetics mimic that of IL-12-p40 mRNA, resulting in a close correlation of individual mRNA levels. Cloning of the IL-18 cDNA from pancreas RNA followed by sequencing revealed identity with the IL-18 sequence cloned from Kupffer cells and in vivo pre-activated macrophages. Also NOD mouse macrophages responded to cyclophosphamide with IL-18 gene expression while macrophages from Balb/c mice treated in parallel did not. Therefore, IL-18 expression is abnormally regulated in autoimmune NOD mice and closely associated with diabetes development (32).

IL-18 plays a potential role in immunoregulation or in inflammation by augmenting the functional activity of Fas ligand on Th1 cells (10). IL-18 is also expressed in the adrenal cortex and therefore might be a secreted neuro-immunomodulator, playing an important role in orchestrating the immune system following a stressful experience (9).

In vivo, IL-18 is formed by cleavage of pro-IL-18, and its endogenous activity appears to account for IFN- γ production in *P. acnes* and LPS-mediated lethality. Because of its activity, blocking the biological activity of IL-18 in human disease is a therapeutic strategy in many diseases. This can be accomplished using soluble receptors or blocking antibodies to the cell-bound IL-18 receptor.

Cytokine binding proteins (soluble cytokine receptors) correspond to the extracellular ligand binding domains of their respective cell surface cytokine receptors. They are derived either by alternative splicing of a pre-mRNA, common to the cell surface receptor, or by proteolytic cleavage of the cell surface receptor. Such soluble receptors have been described in the past, including among others, the soluble receptors of IL-6 and IFN- γ (30), TNF (11, 12), IL-1 and IL-4 (21), IFN- α/β (28, 29) and others. One cytokine-binding protein, named osteoprotegerin (OPG, also known as osteoclast inhibitory factor - OCIF), a member of the TNFR/Fas family, appears to be the first example of a soluble receptor that exists only as a secreted protein (1, 34, 39).

Summary of the Invention

The present invention provides IL-18 binding proteins (IL-18BPs) and virally encoded IL-18BP homologues (hereinafter, viral IL-18BPs), and fused proteins, muteins, functional derivatives, active fragments and circularly permuted derivatives thereof,

capable of binding to IL-18. The invention also provides a process for isolating IL-18BPs from human fluids, and a process to obtain them by recombinant means. The invention also provides expression vectors of IL-18BPs, suitable for expression of IL-18BP in humans and other mammals. Specific IL-18BPs, virally encoded IL-18BP homologues, fused proteins, muteins, functional derivatives, active fragments and circularly permuted derivatives thereof of the present invention are useful for modulating and/or blocking the biological activities of IL-18.

Replicable expression vehicles containing DNAs suitable for expression of the various IL-18BPs in host cells, host cells transformed herewith and proteins and polypeptides produced by expression of such hosts are also provided.

The invention further provides pharmaceutical compositions consisting of suitable vehicles and IL-18BPs, or viral IL-18BPs, or vectors for expressing same in humans and other mammals, for the treatment of diseases or conditions which require modulation or blocking of IL-18 activity.

The invention further provides antibodies to the IL-18BPs and the viral IL-18BPs, suitable for affinity purification and immunoassays of same.

Description of the Figures

Figure 1 shows SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) of ligand affinity purified IL-18 binding protein. Crude urinary proteins (concentrated by ultrafiltration of 500 L normal human urine) were loaded on an IL-18-agarose column. The column was washed and bound proteins eluted at pH 2.2. Eluted fractions were neutralized and aliquots were analyzed by SDS-PAGE (10% acrylamide) under non-reducing conditions and silver staining. The lanes are: 1: crude urinary proteins (1.5 µg, loaded on the gel); 2-9: elutions 1-8, respectively, from the IL-18-agarose column; 10: molecular weight markers, in kD, as indicated on the right side. An arrow indicates the band corresponding to IL-18BP.

Figure 2 shows an autoradiogram of SDS-PAGE (7.5 % acrylamide) of complexes consisting of ¹²⁵I-IL-18 (apparent molecular weight 19 kD), cross-linked to the following

preparations of soluble IL-18 binding protein: Lane 1: Wash of the IL-18 affinity column. Lane 2: Elution 2 of the IL-18 affinity column. Lane 3: Elution 3 of the IL-18 affinity column. Molecular weight markers are indicated on the right side (in kD). An arrow indicates the cross-linked product (58 kD).

5

Figure 3 shows inhibition of IL-18-induced production of IFN- γ by IL-18BP

(A) Mouse splenocytes were stimulated (24 hr, 37°C) with the indicated combinations of LPS (1 μ g/ml) and human IL-18 (5 ng/ml), added either directly, or after pre-mixing (1 h, 37°C) with urinary IL-18BP. The level of muIFN- γ in the culture was determined after 24 hr.

10 (B) Mouse splenocytes were incubated (24 h) with LPS (1 μ g/ml) together with murine IL-18 (10 ng/ml) pre-mixed (1 h, 37°C) with increasing concentrations of human IL-18BP.

(C) Mouse splenocytes were incubated (24 h) with LPS (10 μ g/ml) together with increasing concentrations of human IL-18BP.

15 (D) Mouse splenocytes were incubated (24 h) with Con A (1 μ g/ml), together with increasing concentrations of human IL-18BP.

(E) Human KG-1 cells were stimulated with TNF- α (20 ng/ml) and huIL-18 (25 ng/ml), added either alone, or after pre-mixing (1 h, 37°C) with urinary IL-18BP.

20 **Figure 4** shows the sequence of human IL-18BP_a cDNA and protein. The signal peptide is underlined.

Figure 5 shows the sequence of human IL-18BP_b cDNA and protein. The signal peptide is underlined.

25 **Figure 6** shows the sequence of human IL-18BP_c cDNA and protein. The signal peptide is underlined.

Figure 7 shows the sequence of human IL-18BP_d cDNA and protein. The signal peptide is underlined.

30

Figure 8 shows the sequence of human IL-18BP gene. The sequence of a human genomic clone (7.1 kb) was determined and compared with that of the various cDNA clones isolated from 3 cDNA libraries. the common translation start codon is nucleotides 683-685. The NuMA1 gene is located on the negative strand, from nucleotide 3578 to the end.

5

Figure 9 shows the effect of recombinant IL-18BP on human and mouse IL-18 activity.

His₆-tagged IL-18BP_a was transiently expressed in COS7 cells and purified.

(A) Human IL-18 (5 ng/ml) was pre-mixed with either His₆-tagged-IL-18BP_a or RPMI and added to mouse spleen cells together with LPS (1 µg/ml). IFN-γ production was measured after 24 h.

(B) Mouse IL-18 (10 ng/ml) was pre-mixed with either His₆-tagged-IL-18BP_a or RPMI and added to mouse spleen cells together with LPS (1 µg/ml). IFN-γ production was measured after 24 h.

(C) Human IL-18 (25 ng/ml) was pre-mixed with either COS7-IL-18BP_a or RPMI and added to Human PBMC in the presence of IL-12 (10 ng/ml).

(D) Human IL-18 (25 ng/ml) was pre-mixed with either COS7-IL-18BP_a or RPMI and added to Human KG-1 cells in the presence of TNF-α (20 ng/ml).

20 **Detailed Description of the Invention**

The present invention relates to various IL-18BPs and viral IL-18BPs which bind to IL-18. Such IL-18BPs may be capable of modulating and/or blocking the biological activities of IL-18. The term, "IL-18BPs and viral IL-18BPs," includes the mature protein (without the signal sequence), the protein comprising signal sequences, muteins of IL-18BPs and viral IL-18BPs, derivatives of IL-18BPs and viral IL-18BPs and truncated forms of IL-18BPs and viral IL-18BPs and salts thereof.

The invention further relates to replicable expression vehicles, suitable for expression of various IL-18BPs or viral IL-18BPs in host cells and host bacteria. The invention further relates to expression vectors, suitable for expression of various IL-18BPs or viral IL-18BPs in humans and in other mammals.

The invention further relates to DNAs coding for various IL-18BPs, viral IL-18BPs, muteins, fused proteins, functional derivatives, active fractions and mixtures thereof. Said DNA may be a genomic DNA, a cDNA, a synthetic DNA, a PCR product or combinations thereof. These DNAs may be inserted into replicable expression vehicles for expression of various IL-18BPs and viral IL-18BPs in host cells, according to the invention. DNAs capable of hybridizing to the above DNAs under stringent conditions and encoding proteins or polypeptides which are also capable of binding IL-18 are also included in the present invention.

One such DNA encodes an IL-18BP including the amino acid sequence of SEQ ID NO:10 and provided with a stop codon at its 3' end.

The expression vectors, suitable for expression of various IL-18BPs or viral IL-18BPs in humans and in other mammals, i.e. for gene therapy, may be viral vectors or other types of vectors in which an IL-18BP gene or an IL-18BP cDNA or a DNA encoding a viral IL-18BP was inserted in a way that enables efficient expression of an IL-18BP or a viral IL-18BP in humans and other mammals. DNA molecules hybridizing to the above DNAs under stringent conditions and encoding proteins or polypeptides which are capable of binding IL-18, are also included in the present invention.

Isolation of IL-18BP may be carried out in accordance with the invention, e.g. by passing a human fluid, such as urine or serum, through a chromatographic column to which IL-18 is coupled, and thereafter, eluting the bound IL-18BP.

The various IL-18BPs and viral IL-18BPs can also be prepared by recombinant means, i.e. by expressing IL-18BP in a suitable host, after operatively linking promoters, expression enhancers, regulatory sequences, etc., suitable for the particular host employed which e.g. allow expression in the correct orientation.

The various IL-18BPs and viral IL-18BPs and vectors for expressing IL-18BP in humans and other mammals may be employed in the treatment and alleviation of conditions in which IL-18 is involved or caused by an excess of exogenously administered or endogenously produced IL-18. Such conditions are, e.g., autoimmune diseases, type I diabetes, rheumatoid arthritis, graft rejections, inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart diseases (including heart attacks), ischemic brain injury, chronic hepatitis, psoriasis, chronic pancreatitis, acute pancreatitis and the like.

According to the present invention, IL-18BP was isolated from normal human urine by one chromatographic step. A preparation of crude human urinary proteins concentrated from 500l of normal human urine was loaded on a column consisting of human IL-18 bound to agarose. The column was washed and bound proteins were eluted at low pH. Eluted fractions were neutralized and aliquots were analyzed by SDS-PAGE (10% acrylamide) under non-reducing conditions and silver staining. A protein band of ~40 kD was specifically obtained in the eluted fractions (Fig. 1).

The ~40 kD protein obtained in the first step was identified as an IL-18 binding protein by its ability to specifically cross-link with ¹²⁵I-IL-18 (Fig. 2). The ~40 kD protein was further characterized by N-terminal protein sequence analysis. Aliquots from the eluted protein were subjected to SDS-PAGE, electroblotted to a PVDF membrane and subjected to protein microsequence analysis. Similarly, aliquots from the eluted protein were subjected to direct protein microsequence analysis. In both cases, two polypeptide sequences were obtained. A major sequence and a minor sequence, the latter corresponding to a fragment of human defensin (accession number p11398), starting at amino acid 65. Subtraction of the known defensin sequence provided the following sequence:

T-P-V-S-Q-Q-x-x-x-A-A-A
 1 . . . 5 . . . 10 . .

wherein x represents a yet undetermined amino acid.

In order to obtain a longer and more accurate sequence and in order to identify potential cysteine residues, an aliquot of the eluted fraction was reduced with DTT under denaturing conditions, reacted with 4-vinyl pyridine, desalted by a micro-ultrafiltration device (Ultrafree, cutoff 10,000 Da, Millipore) and subjected to protein microsequence analysis. After sequencing cycle No. 1 the residual protein was reacted with o-phthalaldehyde to block all N-terminal polypeptides other than Pro and sequencing was then resumed. In this way the following single protein sequence was obtained:

TPVSQXXXAA XASVRSTKDP CPSQPPVFPA AKQCPALEVT
 1 10 20 30 40

(T=Thr; P=Pro; V=Val; S=Ser; Q=Gln; X=Unknown; A=Ala; R=Arg; K=Lys; D=Asp; C=Cys; F=Phe; L=Leu; E=Glu)

The resulting sequence is significantly different from that of any other known protein, as determined by searching protein databases. However, searching the database of The Institute of Genomic Research (TIGR) (HTTP://www.ncbi.nlm.nih.gov) by the tblastn search program provided a cDNA file, denoted THC123801, whose open reading frame (218
5 codons), when translated, contains a sequence highly homologous to that of the N-terminal sequence of IL-18BP. The homology is hereby shown:

```

1  . . . . . TPVSQXXXAAXASVRSTKDPCPSQPPVFPAAKQCPALEVT . . . 40
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
51 VTL LV RATXVXQT TTAATASVRSTKDPCPSQPPVFPAAKQCPALEVTWPE 100

```

(The upper sequence (1-40) is that of the IL-18BP isolated according to the invention; the lower sequence (51-100) is deduced by translation of the cDNA of TIGR file THC123801).

The cDNA sequence identified as THC123801 is, however, only an EST (expressed sequence tag), i.e. a randomly selected cDNA clone. It has never been analyzed whether this
15 EST contains an open reading frame, whether a protein is expressed from the gene corresponding to the EST or from the EST itself, nor has any function of a protein encoded by THC123801 ever been identified. No information was available at all that THC123801 contains an open reading frame coding for an IL-18BP.

The affinity-purified urinary IL-18BP retained the ability to bind its labeled ligand
20 (125 I-IL-18), and following covalent cross-linking, a complex of molecular weight 58 kD was formed. The molecular weight of this complex corresponded to a 1:1 ratio of the ~40 kD IL-18BP and the 19 kD IL-18 (Fig. 2).

The affinity-purified urinary IL-18BP blocked the biological activity of human as well as mouse IL-18. Thus when IL-18BP was added to either human or mouse IL-18 it
25 blocked the ability of IL-18 to induce the production of interferon- γ when added together with lipopolysaccharide (LPS) to cultures of mouse spleen cells (Fig. 3).

For the purpose of the present description the expression "biological activity of IL-18" refers inter alia to at least one of the following biological properties :

- (i) induction of IFN- γ , primarily as a co-stimulant with mitogens, IL-1, IL-12,
30 TNF- α , LPS in various cell types, such as mononuclear cells, murine

splenocytes, human peripheral blood mononuclear cells, the human KG-1 cell line and T-cells,

- (ii) enhancement of T-cell proliferation,
- (iii) enhancement of Th-1 cytokine production *in vitro*, primarily as a co-stimulant,
- (iv) synergism with IL-12 in terms of enhanced IFN- γ production, co-stimulatory action for production of IFN- γ and other T-helper cell-1 cytokines,
- (v) co-stimulatory action for FAS ligand-mediated cytotoxicity of murine natural killer cell clones,
- (vi) induction of the activation of NF- κ B in human KG-1 cells, probably by inducing the formation of the 50 NF- κ B homodimer and the p65/p50 NF- κ B heterodimer,
- (vii) induction of IL-8.

As used herein, the expression "binding to IL-18" means the capability of IL-18BP to bind IL-18, e.g. as evidenced by its binding to labeled IL-18 when affinity purified as in Example 2 herein.

As used herein, the expression "modulating the activity of IL-18" means the capability of IL-18BP to modulate any IL-18 activity other than blocking, e.g. partial inhibition, enhancement, or the like.

As used herein, the expression "blocking the activity of IL-18" refers to the activity of IL-18BP to block at least one of the above exemplified biological activities of IL-18. The IL-18 blocking activity of IL-18BP is exemplified by the ability of IL-18BP to block the IL-18 associated IFN- γ expression in murine splenocytes. As it will be shown below in more detail, the modulating or blocking activity of IL-18BP is in part due to the fact that IL-18BP inhibits the activation of NF- κ B by IL-18. Furthermore, IL-18BP blocks at least one of the following activities of IL-18, namely induction of IFN- γ in human and mouse cells, induction of IL-8 and activation of NF- κ B.

A DNA probe for screening cDNA libraries was prepared by reverse-transcription PCR with specific sense and antisense primers and RNA from the human Jurkat T cells with primers from the TIGR sequence. The resulting PCR product was confirmed by DNA

sequence analysis. This PCR product was labeled with ^{32}P and used as a probe for screening of four human cDNA libraries, derived from peripheral blood monocytes, from the Jurkat T-cell line, from PBMC and from human spleen. The various independent cDNA clones corresponded to four IL-18BP splice variants (SEQ ID NO:1, 3, 5 and 7). All splice variants coded for putative soluble secreted proteins. The most abundant one (IL-18BP_a) had an open reading frame of 192 codons, coding for a signal peptide herein sometimes referred to as a "leader sequence" of 28 amino acid residues followed by a mature putative IL-18BP_a, whose first 40 residues matched perfectly with the N-terminal protein sequence of the urinary IL-18BP (SEQ ID NO:2). The position of the cysteine residues suggested that this polypeptide belongs to the immunoglobulin (Ig) super-family. Interestingly, each of the four Gln residues within mature IL-18BP_a was a potential N-glycosylation site. The three other variants of IL-18BP were less abundant than IL-18BP_a. They included a shorter 1 kb IL-18BP_b cDNA, coding for a signal peptide of 28 amino acid residues followed by a mature protein of 85 amino acid residues (SEQ ID NO:4). A third variant, IL-18BP_c was represented by a 2.3 kb cDNA, coding for a signal peptide of 28 amino acid residues followed by a mature IL-18BP of 169 amino acid residues (SEQ ID NO:6). The fourth variant, IL-18BP_d, coded for a signal peptide of 28 amino acid residues followed by a mature IL-18BP of 133 amino acid residues (SEQ ID NO:8).

To further study the possible existence of additional IL-18BP splice variants, a human genomic library was screened with a probe corresponding to full length IL-18BP cDNA. Five genomic clones, differing in length, were identified in this library. These clones were subjected to DNA sequence analysis with external and internal primers. Altogether, a 7.8 kb sequence was assembled from these clones (SEQ ID NO:9). No exon coding for a trans-membrane (TM) receptor was identified within the 7.8 kb sequence. All variants shared a common translation start site, coded for the same signal peptide of 28 amino acid residues and soluble mature proteins of varying sizes and C-terminal sequences. The IL-18BP locus contains an additional gene, coding for the nuclear mitotic apparatus protein 1 (NUMA1), positioned at the minus strand. This finding localizes the IL-18BP gene to human chromosome 11q13 (36).

An homology search was done with the complete protein sequence of IL-18BP_a and the GenPept database ([HTTP://www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)), using the Smith Watermann

algorithm. It was found that homologues of IL-18BP are expressed in several Poxviruses as secreted proteins of a previously unknown function. It was previously reported that viruses code for various cytokine receptors and that such virally encoded molecules serve as decoy receptors that inhibit immune responses by neutralizing their corresponding cytokine (reviewed by Spriggs, MK, 1994, Curr. Opin. Immunol., 6, 526-529). Therefore the invention further relates to virally encoded homologues of IL-18BP that may also serve as blockers or modulators of the biological activity of IL-18. Examples of virus-encoded homologues of IL-18BP are provided in Table 1.

According to the present invention the virus encoded homologue of IL-18BP may be expressed in a prokaryotic or eukaryotic host. As used herein, the expression "virus encoded homologue IL-18BP" refers to a similarity of at least 50% in a sequence of at least 70 amino acid residues. More preferably, it has at least 50%, at least 60%, at least 70%, at least 80% or, most preferably, at least 90% similarity thereto in a sequence of 100 amino acid residues.

Table 1. Virus-encoded proteins, showing high homology to human IL-18BP

GenPept sequence	Virus type
MCU60315_54	U60315 Molluscum contagiosum virus subtype 1
MCU60315_53	U60315 Molluscum contagiosum virus subtype 1
SWPHLSB_12	L22013 Swinepox virus
CV41KBPL_14	Cowpox virus
VVCGAA_5	Variola virus
U01161_3 174	Ectromelia virus (mouse Poxvirus)
VVU18340_6	Variola virus
VVU18338_7	Variola virus
VVU18337_7	Variola virus
VARCG_7 173	Variola major virus
MCU60315_51	Molluscum contagiosum virus
HNABV_1	New Hepatitis non-A, non-B associated virus

IL-18BP_a was expressed in monkey COS7 cells. For this purpose, the cDNA of IL-18BP_a was inserted into the mammalian expression vector pEF-BOS. A cassette coding for an (His)₆ sequence was added to the 3'-end of the IL-18BP ORFs in frame, in order to facilitate purification of the recombinant protein. COS7 cells were transiently transfected with the expression vector and serum-free medium of these cells (150 ml) was concentrated and purified by metal chelate chromatography. IL-18BP_a ran as a single band upon SDS-PAGE with silver staining under reducing and non-reducing conditions and had the same apparent molecular mass as that of the urinary IL-18BP. Protein sequence analysis of this preparation revealed the same N-terminal sequence as that of the urinary IL-18BP. Immunoblot analysis of IL-18BP_a with antibodies raised against the urinary IL-18BP revealed the same molecular mass band as that of the urinary protein. Furthermore, using immunoprecipitation followed by SDS-PAGE and autoradiography, IL-18BP_a was able to displace urinary ¹²⁵I-IL-18BP from binding to the antibody. Therefore, IL-18BP_a corresponds structurally to the IL-18BP isolated from urine.

Crude and purified IL-18BP_a were tested for their ability to inhibit the biological activity of IL-18. IL-18BP_a inhibited the activity of human and mouse IL-18 in murine splenocytes, PBMC and the human KG-1 cell line (Fig. 9). These results confirm the identity of IL-18BP_a cDNA as the one coding for a biologically active IL-18BP.

The invention further relates to muteins and fragments of IL-18BPs and viral IL-18BPs and to fused proteins consisting of wild type IL-18BPs and viral IL-18BPs or their muteins or their fragments, fused to another polypeptide or protein and being capable of binding IL-18 or its homologues.

As used herein the term "muteins" refers to analogs of an IL-18BP, or analogs of a viral IL-18BP, in which one or more of the amino acid residues of a natural IL-18BP or viral IL-18BP are replaced by different amino acid residues, or are deleted, or one or more amino acid residues are added to the natural sequence of an IL-18BP, or a viral IL-18BP, without changing considerably the capability of the resulting products as compared with the wild type IL-18BP or viral IL-18BP to bind to IL-18. These muteins are prepared by known synthesis and/or by site-directed mutagenesis techniques, or any other known technique suitable therefor.

Any such mutein preferably has a sequence of amino acids sufficiently duplicative of that of an IL-18BP, or sufficiently duplicative of a viral IL-18BP, such as to have substantially similar activity to IL-18BP. One activity of IL-18BP is its capability of binding IL-18. As long as the mutein has substantial binding activity to IL-18, it can be used in the purification of IL-18, such as by means of affinity chromatography, and thus can be considered to have substantially similar activity to IL-18BP. Thus, it can be determined whether any given mutein has substantially the same activity as IL-18BP by means of routine experimentation comprising subjecting such a mutein, *e.g.*, to a simple sandwich competition assay to determine whether or not it binds to an appropriately labeled IL-18, such as radioimmunoassay or ELISA assay.

In a preferred embodiment, any such mutein has at least 40% identity or homology with the sequence of either an IL-18BP or a virally-encoded IL-18BP homologue. More preferably, it has at least 50%, at least 60%, at least 70%, at least 80% or, most preferably, at least 90% identity or homology thereto.

Muteins of IL-18BP polypeptides or muteins of viral IL-18BPs, which can be used in accordance with the present invention, or nucleic acid coding therefor, include a finite set of substantially corresponding sequences as substitution peptides or polynucleotides which can be routinely obtained by one of ordinary skill in the art, without undue experimentation, based on the teachings and guidance presented herein. For a detailed description of protein chemistry and structure, see Schulz, G.E. et al., *Principles of Protein Structure*, Springer-Verlag, New York, 1978; and Creighton, T.E., *Proteins: Structure and Molecular Properties*, W.H. Freeman & Co., San Francisco, 1983, which are hereby incorporated by reference. For a presentation of nucleotide sequence substitutions, such as codon preferences, see Ausubel et al, *supra*, at §§ A.1.1-A.1.24, and Sambrook et al, *supra*, at Appendices C and D.

Preferred changes for muteins in accordance with the present invention are what are known as "conservative" substitutions. Conservative amino acid substitutions of IL-18BP polypeptides or proteins or viral IL-18BPs, may include synonymous amino acids within a group which have sufficiently similar physicochemical properties that substitution between members of the group will preserve the biological function of the molecule, Grantham, *Science*, Vol. 185, pp. 862-864 (1974). It is clear that insertions and deletions of amino acids

may also be made in the above-defined sequences without altering their function, particularly if the insertions or deletions only involve a few amino acids, *e.g.*, under thirty, and preferably under ten, and do not remove or displace amino acids which are critical to a functional conformation, *e.g.*, cysteine residues, Anfinsen, "Principles That Govern The Folding of Protein Chains", Science, Vol. 181, pp. 223-230 (1973). Proteins and muteins produced by such deletions and/or insertions come within the purview of the present invention.

However, cysteine residues which are not required for biological activity may be replaced with other residues, *e.g.* in order to avoid the formation of undesired intramolecular or intermolecular disulfide bridges which may cause a reduction in the activity of the IL-18BPs.

Preferably, the synonymous amino acid groups are those defined in Table I. More preferably, the synonymous amino acid groups are those defined in Table II; and most preferably the synonymous amino acid groups are those defined in Table III.

TABLE I**Preferred Groups of Synonymous Amino Acids**

	Amino Acid	Synonymous Group
5	Ser	Ser, Thr, Gly, Asn
	Arg	Arg, Gln, Lys, Glu, His
	Leu	Ile, Phe, Tyr, Met, Val, Leu
	Pro	Gly, Ala, Thr, Pro
	Thr	Pro, Ser, Ala, Gly, His, Gln, Thr
10	Ala	Gly, Thr, Pro, Ala
	Val	Met, Tyr, Phe, Ile, Leu, Val
	Gly	Ala, Thr, Pro, Ser, Gly
	Ile	Met, Tyr, Phe, Val, Leu, Ile
	Phe	Trp, Met, Tyr, Ile, Val, Leu, Phe
15	Tyr	Trp, Met, Phe, Ile, Val, Leu, Tyr
	Cys	Ser, Thr, Cys
	His	Glu, Lys, Gln, Thr, Arg, His
	Gln	Glu, Lys, Asn, His, Thr, Arg, Gln
	Asn	Gln, Asp, Ser, Asn
20	Lys	Glu, Gln, His, Arg, Lys
	Asp	Glu, Asn, Asp
	Glu	Asp, Lys, Asn, Gln, His, Arg, Glu
	Met	Phe, Ile, Val, Leu, Met
	Trp	Trp

25

30

TABLE II**More Preferred Groups of Synonymous Amino Acids**

	Amino Acid	Synonymous Group
5	Ser	Ser
	Arg	His, Lys, Arg
	Leu	Leu, Ile, Phe, Met
	Pro	Ala, Pro
	Thr	Thr
10	Ala	Pro, Ala
	Val	Val, Met, Ile
	Gly	Gly
	Ile	Ile, Met, Phe, Val, Leu
	Phe	Met, Tyr, Ile, Leu, Phe
15	Tyr	Phe, Tyr
	Cys	Cys, Ser
	His	His, Gln, Arg
	Gln	Glu, Gln, His
	Asn	Asp, Asn
20	Lys	Lys, Arg
	Asp	Asp, Asn
	Glu	Glu, Gln
	Met	Met, Phe, Ile, Val, Leu
	Trp	Trp

TABLE III**Most Preferred Groups of Synonymous Amino Acids**

	Amino Acid	Synonymous Group
	Ser	Ser
5	Arg	Arg
	Leu	Leu, Ile, Met
	Pro	Pro
	Thr	Thr
	Ala	Ala
10	Val	Val
	Gly	Gly
	Ile	Ile, Met, Leu
	Phe	Phe
	Tyr	Tyr
15	Cys	Cys, Ser
	His	His
	Gln	Gln
	Asn	Asn
	Lys	Lys
20	Asp	Asp
	Glu	Glu
	Met	Met, Ile, Leu
	Trp	Met

25 Examples of production of amino acid substitutions in proteins which can be used for obtaining muteins of IL-18BP polypeptides or proteins, or muteins of viral IL-18BPs, for use in the present invention include any known method steps, such as presented in US patents RE 33,653, 4,959,314, 4,588,585 and 4,737,462, to Mark et al; 5,116,943 to Koths et al., 4,965,195 to Namen et al; 4,879,111 to Chong et al; and 5,017,691 to Lee et al; and lysine
30 substituted proteins presented in US patent No. 4,904,584 (Shaw et al).

In another preferred embodiment of the present invention, any mutein of an IL-18BP or a viral IL-18BP, has an amino acid sequence essentially corresponding to that of an IL-18BP, or to a viral IL-18BP. The term "essentially corresponding to" is intended to comprehend proteins with minor changes to the sequence of the natural protein which do not affect the basic characteristics of the natural proteins, particularly insofar as their ability to bind IL-18. The type of changes which are generally considered to fall within the "essentially corresponding to" language are those which would result from conventional mutagenesis techniques of the DNA encoding these proteins, resulting in a few minor modifications, and screening for the desired activity in the manner discussed above. In addition to binding IL-18, the muteins may also modulate and/or block IL-18 activity.

Muteins in accordance with the present invention include proteins encoded by a nucleic acid, such as DNA or RNA, which hybridizes to DNA or RNA, which encodes an IL-18BP or encodes a viral IL-18BP, in accordance with the present invention, under stringent conditions. The invention also includes such nucleic acid, which is also useful as a probe in identification and purification of the desired nucleic acid. Furthermore, such nucleic acid would be a prime candidate to determine whether it encodes a polypeptide, which retains the functional activity of an IL-18BP of the present invention. The term "stringent conditions" refers to hybridization and subsequent washing conditions, which those of ordinary skill in the art conventionally refer to as "stringent". See Ausubel et al., Current Protocols in Molecular Biology, *supra*, Interscience, N.Y., §§6.3 and 6.4 (1987, 1992), and Sambrook et al., *supra*. Without limitation, examples of stringent conditions include washing conditions 12-20°C below the calculated T_m of the hybrid under study in, *e.g.*, 2 x SSC and 0.5% SDS for 5 minutes, 2 x SSC and 0.1% SDS for 15 minutes; 0.1 x SSC and 0.5% SDS at 37°C for 30-60 minutes and then, a 0.1 x SSC and 0.5% SDS at 68°C for 30-60 minutes. Those of ordinary skill in this art understand that stringency conditions also depend on the length of the DNA sequences, oligonucleotide probes (such as 10-40 bases) or mixed oligonucleotide probes. If mixed probes are used, it is preferable to use tetramethyl ammonium chloride (TMAC) instead of SSC. See Ausubel, *supra*.

The invention further includes nucleic acids which code for IL-18BP according to the present invention, but which differ in codon sequence due to the degeneracy of the genetic

code. Such a DNA which possibly does not hybridize under stringent conditions to the DNA sequences shown in Figures 4 to 7, but is nevertheless capable of encoding an IL-18BP according to the present invention is also included by the invention.

The term "fused protein" refers to a polypeptide comprising an IL-18BP, or a viral
5 IL-18BP, or a mutein thereof, fused with another protein, which, *e.g.*, has an extended residence time in body fluids. An IL-18BP or a viral IL-18BP, may thus be fused to another protein, polypeptide or the like, *e.g.*, an immunoglobulin or a fragment thereof. It may also be fused to polyethylene glycol (PEG) in order to prolong residence time.

The term "salts" herein refers to both salts of carboxyl groups and to acid addition
10 salts of amino groups of an IL-18BP, a viral IL-18BP, muteins, or fused proteins thereof. Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases as those formed, for example, with amines, such as triethanolamine, arginine or lysine, piperidine, procaine and the like. Acid addition salts include, for example,
15 salts with mineral acids such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids such as, for example, acetic acid or oxalic acid. Of course, any such salts must have substantially similar activity to IL-18BP.

"Functional derivatives" as used herein cover derivatives of IL-18BPs or a viral
IL-18BP, and their muteins and fused proteins, which may be prepared *e.g.* from the
20 functional groups which occur as side chains on the residues or the N- or C-terminal groups, by means known in the art, and are included in the invention as long as they remain pharmaceutically acceptable, *i.e.* they do not destroy the activity of the protein which is substantially similar to the activity of IL-18BP, or viral IL-18BPs, and do not confer toxic properties on compositions containing it. These derivatives may, for example, include
25 polyethylene glycol side-chains, which may mask antigenic sites and extend the residence of an IL-18BP or a viral IL-18BP in body fluids. Other derivatives include aliphatic esters of the carboxyl groups, amides of the carboxyl groups by reaction with ammonia or with primary or secondary amines, N-acyl derivatives of free amino groups of the amino acid residues formed with acyl moieties (*e.g.* alkanoyl or carbocyclic aroyl groups) or O-acyl derivatives of

free hydroxyl groups (for example that of seryl or threonyl residues) formed with acyl moieties.

As "active fractions" of an IL-18BP, or a viral IL-18BP, muteins and fused proteins, the present invention covers any fragment or precursors of the polypeptide chain of the protein molecule alone or together with associated molecules or residues linked thereto, *e.g.*,
5 sugar or phosphate residues, or aggregates of the protein molecule or the sugar residues by themselves, provided said fraction substantially retains the capability of binding IL-18.

The term "circularly permuted derivatives" as used herein refers to a linear molecule in which the termini have been joined together, either directly or through a linker, to produce a circular molecule, and then the circular molecule is opened at another location to produce a
10 new linear molecule with termini different from the termini in the original molecule. Circular permutations include those molecules whose structure is equivalent to a molecule that has been circularized and then opened. Thus, a circularly permuted molecule may be synthesized *de novo* as a linear molecule and never go through a circularization and opening step. The
15 preparation of circularly permuted derivatives is described in WO95/27732.

Various recombinant cells such as prokaryotic cells, *e.g.*, *E. coli*, or other eukaryotic cells, such as yeast or insect cells can produce IL-18BPs or viral IL-18BPs. Methods for constructing appropriate vectors, carrying DNA that codes for an IL-18BP and suitable for transforming (*e.g.*, *E. coli*, mammalian cells and yeast cells), or infecting insect cells in order
20 to produce a recombinant IL-18BP or a viral IL-18BP are well known in the art. See, for example, Ausubel et al., eds. "Current Protocols in Molecular Biology" Current Protocols, 1993; and Sambrook et al., eds. "Molecular Cloning: A Laboratory Manual", 2nd ed., Cold Spring Harbor Press, 1989.

For the purposes of expression of IL-18BP proteins, or viral IL-18BPs, DNA
25 encoding an IL-18BP or a viral IL-18BP, their fragments, muteins or fused proteins, and the operably linked transcriptional and translational regulatory signals, are inserted into vectors which are capable of integrating the desired gene sequences into the host cell chromosome. In order to be able to select the cells which have stably integrated the introduced DNA into their chromosomes, one or more markers which allow for selection of host cells which
30 contain the expression vector is used. The marker may provide for prototrophy to an auxotrophic host, biocide resistance, *e.g.*, antibiotics, or resistance to heavy metals, such as

copper, or the like. The selectable marker gene can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by cotransfection. Additional elements may also be needed for optimal synthesis of single chain binding protein mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals.

Said DNA molecule to be introduced into the cells of choice will preferably be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Preferred prokaryotic plasmids are derivatives of pBr322. Preferred eukaryotic vectors include BPV, vaccinia, SV40, 2-micron circle, etc., or their derivatives. Such plasmids and vectors are well known in the art (2-5, 22). Once the vector or DNA sequence containing the construct(s) has been prepared for expression, the expression vector may be introduced into an appropriate host cell by any of a variety of suitable means, such as transformation, transfection, lipofection, conjugation, protoplast fusion, electroporation, calcium phosphate precipitation, direct microinjection, etc.

Host cells to be used in this invention may be either prokaryotic or eukaryotic. Preferred prokaryotic hosts include bacteria such as E. coli, Bacillus, Streptomyces, Pseudomonas, Salmonella, Serratia, etc. The most preferred prokaryotic host is E. coli. Bacterial hosts of particular interest include E. coli K12 strain 294 (ATCC 31446), E. coli X1776 (ATCC 31537), E. coli W3110 (F⁻, lambda⁻, phototropic (ATCC 27325). Under such conditions, the protein will not be glycosylated. The prokaryotic host must be compatible with the replicon and control sequences in the expression plasmid.

However, since natural IL-18BPs are glycosylated proteins, eukaryotic hosts are preferred over prokaryotic hosts. Preferred eukaryotic hosts are mammalian cells, *e.g.*, human, monkey, mouse and Chinese hamster ovary (CHO) cells, because they provide post-translational modifications to protein molecules including correct folding, correct disulfide bond formation, as well as glycosylation at correct sites. Also yeast cells and insect cells can carry out post-translational peptide modifications including high mannose glycosylation.

A number of recombinant DNA strategies exist which utilize strong promoter sequences and high copy number of plasmids, which can be utilized for production of the desired proteins in yeast and in insect cells. Yeast and insect cells recognize leader sequences

on cloned mammalian gene products and secrete mature IL-18BP. After the introduction of the vector, the host cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene sequence(s) results in the production of an IL-18BP, a viral IL-18BP, fusion proteins, or muteins or fragments thereof. The above-mentioned cloning, clone isolation, identification, characterization and sequencing procedures are described in more detail hereinafter in the Examples.

The expressed proteins are then isolated and purified by any conventional procedure involving extraction, precipitation, chromatography, electrophoresis, or the like, or by affinity chromatography, using, e.g., an anti-IL-18BP monoclonal antibodies immobilized on a gel matrix contained within a column. Crude preparations containing said recombinant IL-18BP are passed through the column whereby IL-18BP will be bound to the column by the specific antibody, while the impurities will pass through. After washing, the protein is eluted from the gel under conditions usually employed for this purpose, *i.e.* at a high or a low pH, *e.g.* pH 11 or pH 2.

The invention further relates to vectors useful for expression of an IL-18BP or a viral IL-18BP or their derivatives in mammals and more specifically in humans. Vectors for short and long-term expression of genes in mammals are well known in the literature. Studies have shown that gene delivery to e.g., skeletal muscle, vascular smooth muscle and liver result in systemic levels of therapeutic proteins. Skeletal muscle is a useful target because of its large mass, vascularity and accessibility. However, other targets and particularly bone marrow precursors of immune cells have been used successfully. Currently available vectors for expression of proteins in e.g., muscle include plasmid DNA, liposomes, protein-DNA conjugates and vectors based on adenovirus, adeno-associated virus and herpes virus. Of these, vectors based on adeno-associated virus (AAV) have been most successful with respect to duration and levels of gene expression and with respect to safety considerations (Kessler, P.D. 1996, Proc. Natl. Acad. Sci. USA 93, 14082-14087).

Procedures for construction of an AAV-based vector have been described in detail (Snyder et al, 1996, Current Protocols in Human Genetics, Chapters 12.1.1-12.1.17, John Wiley & Sons) and are incorporated into this patent. Briefly plasmid psub201, containing the wild-type AAV genome is cut with the restriction enzyme Xba I and ligated with a construct

consisting of an efficient eukaryotic promoter, e.g., the cytomegalovirus promoter, a Kozak consensus sequence, a DNA sequence coding for an IL-18BP or a viral IL-18BP, or their muteins or fusion proteins or fragments thereof, a suitable 3' untranslated region and a polyadenylation signal, e.g., the polyadenylation signal of simian virus 40. The resulting recombinant plasmid is cotransfected with an helper AAV plasmid e.g., pAAV/Ad into mammalian cells e.g., human T293 cells. The cultures are then infected with adenovirus as a helper virus and culture supernatants are collected after 48-60 hours. The supernatants are fractionated by ammonium sulfate precipitation, purified on a CsCl density gradient, dialyzed and then heated at 56°C to destroy any adenovirus, whereas the resulting recombinant AAV, capable of expressing IL-18BP or a viral IL-18BP, or their muteins or fusion proteins remains stable at this step.

So far, the physiological role of the soluble cytokine receptors has not been established. The soluble receptors bind their specific ligands and in most cases inhibit their biological activity, as was shown, e.g., in the TNF system (11, 12). In very few cases, e.g., IL-6, the soluble receptor enhances the biological activity. The recombinant soluble TNF receptor, also known as TBP (TNF binding protein) was found to prevent septic shock in animal models, while soluble forms of IL-1 receptor were found to have profound inhibitory effects on the development of in vivo alloreactivity in mouse allograft recipients.

Similarly, the IL-18BPs and viral IL-18BPs of the present invention may find use as modulators of IL-18 activity, e.g. in type I diabetes, in sepsis, in autoimmune diseases, in graft rejections, rheumatoid arthritis, inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart disease including acute heart attacks, ischemic brain injury, chronic hepatitis, psoriasis, chronic hepatitis and acute hepatitis. They may thus be used, e.g. in any disease in which endogenous production or exogenous administration of IL-18 induces the disease or aggravates the situation of the patient.

The present invention further relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an IL-18BP or a viral IL-18BP of the invention or their active muteins, fused proteins and their salts, functional derivatives or active fractions thereof.

The present invention further relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and e.g., a viral vector such as any one of said

AAV-based viral vectors or another vector expressing an IL-18BP or viral IL-18BP or their muteins, fragments or fusion proteins thereof and suitable for administration to humans and other mammals for the purpose of attaining expression in vivo of IL-18BP or a viral IL-18BP or their muteins or fragments or fusion protein of the invention, i.e. for use in gene therapy.

5 The pharmaceutical compositions of the invention are prepared for administration by mixing an IL-18BP or a viral IL-18BP, or their derivatives, or vectors for expressing same with physiologically acceptable carriers, and/or stabilizers and/or excipients, and prepared in dosage form, *e.g.*, by lyophilization in dosage vials. The method of administration can be via any of the accepted modes of administration for similar agents and will depend on the
10 condition to be treated, *e.g.*, intravenously, intramuscularly, subcutaneously, by local injection or topical application, or continuously by infusion, etc. The amount of active compound to be administered will depend on the route of administration, the disease to be treated and the condition of the patient. Local injection, for instance, will require a lower amount of the protein on a body weight basis than will intravenous infusion.

15 Accordingly, IL-18BPs, or viral IL-18BPs, or vectors expressing same in vivo are indicated for the treatment of autoimmune diseases, Type I diabetes, rheumatoid arthritis, graft rejections, inflammatory bowel disease, sepsis, multiple sclerosis, ischemic heart disease including acute heart attacks, ischemic brain injury, chronic hepatitis, psoriasis, chronic pancreatitis and acute pancreatitis and similar diseases, in which there is an aberrant
20 expression of IL-18, leading to an excess of IL-18 or in cases of complications due to exogenously administered IL-18.

 The invention also includes antibodies against an IL-18BP or a viral IL-18BP, as well as against their muteins, fused proteins, salts, functional derivatives and active fractions. The term "antibody" is meant to include polyclonal antibodies, monoclonal antibodies (MAbs),
25 chimeric antibodies, anti-idiotypic (anti-Id) antibodies to antibodies that can be labeled in soluble or bound form, and humanized antibodies as well as fragments thereof provided by any known technique, such as, but not limited to enzymatic cleavage, peptide synthesis or recombinant techniques.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen. A monoclonal antibody contains a substantially homogeneous population of antibodies specific to antigens, which population contains substantially similar epitope binding sites. MAbs may be obtained by methods known to those skilled in the art. See, for example Kohler and Milstein, Nature 256:495-497 (1975); US Patent No. 4,376,110; Ausubel et al, eds., supra, Harlow and Lane, ANTIBODIES: A LABORATORY MANUAL, Cold Spring Harbor Laboratory (1988); and Colligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1992, 1993), the contents of which references are incorporated entirely herein by reference. Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, GILD and any subclass thereof. A hybridoma producing a MAb of the present invention may be cultivated *in vitro*, *in situ* or *in vivo*. Production of high titers of MAbs *in vivo* or *in situ* makes this the presently preferred method of production.

Chimeric antibodies are molecules, different portions of which are derived from different animal species, such as those having the variable region derived from a murine MAb and a human immunoglobulin constant region. Chimeric antibodies are primarily used to reduce immunogenicity in application and to increase yields in production, for example, where murine MAbs have higher yields from hybridomas but higher immunogenicity in humans, such that human/murine chimeric MAbs are used. Chimeric antibodies and methods for their production are known in the art (Cabilly et al, Proc. Natl. Acad. Sci. USA 81:3273-3277 (1984); Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984); Boulianne et al., Nature 312:643-646 (1984); Cabilly et al., European Patent Application 125023 (published November 14, 1984); Neuberger et al., Nature 314:268-270 (1985); Taniguchi et al., European Patent Application 171496 (published February 19, 1985); Morrison et al., European Patent Application 173494 (published March 5, 1986); Neuberger et al., PCT Application WO 8601533, (published March 13, 1986); Kudo et al., European Patent Application 184187 (published June 11, 1986); Morrison et al., European Patent Application 173494 (published March 5, 1986); Sahagan et al., J. Immunol. 137:1066-1074 (1986); Robinson et al., International Patent Publication, WO 9702671 (published 7 May 1987); Liu et al., Proc. Natl. Acad. Sci. USA 84:3439-3443 (1987); Sun et al., Proc. Natl.

Acad. Sci. USA 84:214-218 (1987); Better et al., Science 240:1041- 1043 (1988); and Harlow and Lane, ANTIBODIES: A LABORATORY MANUAL, supra. These references are entirely incorporated herein by reference.

5 An anti-idiotypic (anti-Id) antibody is an antibody, which recognizes unique determinants generally, associated with the antigen-binding site of an antibody. An Id antibody can be prepared by immunizing an animal of the same species and genetic type (e.g., mouse strain) as the source of the MAb with the MAb to which an anti-Id is being prepared. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing antibody by producing an antibody to these idiotypic determinants (the
10 anti-Id antibody). See, for example, US patent No. 4,699,880, which is herein entirely incorporated by reference.

The anti-Id antibody may also be used as an "immunogen" to induce an immune response in yet another animal, producing a so-called anti-anti-Id antibody. The anti-anti-Id may be epitopically identical to the original MAb, which induced the anti-Id. Thus, by using
15 antibodies to the idiotypic determinants of a MAb, it is possible to identify other clones expressing antibodies of identical specificity.

Accordingly, MAbs generated against IL-18BP and related proteins of the present invention may be used to induce anti-Id antibodies in suitable animals, such as BALB/c mice. Spleen cells from such immunized mice are used to produce anti-Id hybridomas
20 secreting anti-Id MAbs. Further, the anti-Id MAbs can be coupled to a carrier such as keyhole limpet hemocyanin (KLH) and used to immunize additional BALB/c mice. Sera from these mice will contain anti-anti-Id antibodies that have the binding properties of the original MAb specific for an IL-18BP epitope or epitopes of a viral IL-18BP.

The anti-Id MAbs thus have their own idiotypic epitopes, or "idiotopes" structurally
25 similar to the epitope being evaluated, such as an IL-18BP or a viral IL-18BP.

The term "humanized antibody" is meant to include e.g. antibodies which were obtained by manipulating mouse antibodies through genetic engineering methods so as to be more compatible with the human body. Such humanized antibodies have reduced

immunogenicity and improved pharmacokinetics in humans. They may be prepared by techniques known in the art, such as described, e.g. for humanized anti-TNF antibodies in Molecular Immunology, Vol. 30, No. 16, pp. 1443-1453, 1993.

The term "antibody" is also meant to include both intact molecules as well as
5 fragments thereof, such as, for example, Fab and F(ab')₂, which are capable of binding antigen. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl et al., J. Nucl. Med. 24:316-325 (1983)). It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies useful in the present invention may be used for
10 the detection and quantitation of an IL-18BP or a viral IL-18BP, according to the methods disclosed herein for intact antibody molecules. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments).

An antibody is said to be "capable of binding" a molecule if it is capable of
15 specifically reacting with the molecule to thereby bind the molecule to the antibody. The term "epitope" is meant to refer to that portion of any molecule capable of being bound by an antibody which can also be recognized by that antibody. Epitopes or "antigenic determinants" usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and have specific three dimensional structural
20 characteristics as well as specific charge characteristics.

An "antigen" is a molecule or a portion of a molecule capable of being bound by an antibody which is additionally capable of inducing an animal to produce antibody capable of binding to an epitope of that antigen. An antigen may have one or more than one epitope. The specific reaction referred to above is meant to indicate that the antigen will react, in a
25 highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.

The antibodies, including fragments of antibodies, useful in the present invention may be used to detect quantitatively or qualitatively an IL-18BP or a viral IL-18BP, or

related proteins in a sample or to detect presence of cells, which express such proteins of the present invention. This can be accomplished by immunofluorescence techniques employing a fluorescently labeled antibody (see below) coupled with light microscopic, flow cytometric, or fluorometric detection.

5 The antibodies (or fragments thereof) useful in the present invention may be employed histologically, as in immunofluorescence or immunoelectron microscopy, for *in situ* detection of an IL-18BP or a viral IL-18BP, and related proteins of the present invention. *In situ* detection may be accomplished by removing a histological specimen from a patient, and providing the a labeled antibody of the present invention to such a specimen. The
10 antibody (or fragment) is preferably provided by applying or by overlaying the labeled antibody (or fragment) to a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of an IL-18BP or a viral IL-18BP, or related proteins but also its distribution on the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of wide variety of histological methods (such as
15 staining procedures) can be modified in order to achieve such *in situ* detection.

Such assays for an IL-18BP or a viral IL-18BP, or related proteins of the present invention typically comprises incubating a biological sample, such as a biological fluid, a tissue extract, freshly harvested cells such as lymphocytes or leukocytes, or cells which have been incubated in tissue culture, in the presence of a detectably labeled antibody capable of
20 identifying IL-18BP or related proteins, and detecting the antibody by any of a number of techniques well-known in the art.

The biological sample may be treated with a solid phase support or carrier such as nitrocellulose, or other solid support or carrier which is capable of immobilizing cells, cell particles or soluble proteins. The support or carrier may then be washed with suitable buffers
25 followed by treatment with a detectably labeled antibody in accordance with the present invention. The solid phase support or carrier may then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on said solid support or carrier may then be detected by conventional means.

By "solid phase support", "solid phase carrier", "solid support", "solid carrier", "support" or "carrier" is intended any support or carrier capable of binding antigen or antibodies. Well-known supports or carriers, include glass, polystyrene, polypropylene, polyethylene, dextran, nylon amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support or carrier configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports or carriers include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

The binding activity of a given lot of antibody in accordance with the present invention may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

Other such steps as washing, stirring, shaking, filtering and the like may be added to the assays as is customary or necessary for the particular situation.

One of the ways in which an antibody in accordance with the present invention can be detectably labeled is by linking the same to an enzyme and use in an enzyme immunoassay (EIA). This enzyme, in turn, when later exposed to an appropriate substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or by visual means. Enzymes which can be used detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha- glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6- phosphate dehydrogenase,

glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods, which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

5 Detection may be accomplished using any of a variety of other immunoassays. For example, by radioactivity labeling the antibodies or antibody fragments, it is possible to detect an IL-18BP or a viral IL-18BP, through the use of a radioimmunoassay (RIA). A good description of RIA maybe found in Laboratory Techniques and Biochemistry in Molecular Biology, by Work, T.S. et al., North Holland Publishing Company, NY (1978) with
10 particular reference to the chapter entitled "An Introduction to Radioimmuno Assay and Related Techniques" by Chard, T., incorporated by reference herein. The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.

 It is also possible to label an antibody in accordance with the present invention with a
15 fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wavelength, its presence can be then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

 The antibody can also be detectably labeled using fluorescence emitting metals such
20 as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriamine pentaacetic acid (ETPA).

 The antibody can also be detectably labeled by coupling it to biotin. Biotinylated antibody can then be detected by avidin or streptavidin coupled to a fluorescent compound or to an enzyme such as peroxidase or to a radioactive isotope and the like.

25 The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.

Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, thermotropic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

An antibody molecule of the present invention may be adapted for utilization in a immunometric assay, also known as a "two-site" or "sandwich" assay. In a typical immunometric assay, a quantity of unlabeled antibody (or fragment of antibody) is bound to a solid support or carrier and a quantity of detectably labeled soluble antibody is added to permit detection and/or quantitation of the ternary complex formed between solid-phase antibody, antigen, and labeled antibody.

Typical, and preferred, immunometric assays include "forward" assays in which the antibody bound to the solid phase is first contacted with the sample being tested to extract the antigen from the sample by formation of a binary solid phase antibody-antigen complex. After a suitable incubation period, the solid support or carrier is washed to remove the residue of the fluid sample, including unreacted antigen, if any, and then contacted with the solution containing an unknown quantity of labeled antibody (which functions as a "reporter molecule"). After a second incubation period to permit the labeled antibody to complex with the antigen bound to the solid support or carrier through the unlabeled antibody, the solid support or carrier is washed a second time to remove the unreacted labeled antibody.

In another type of "sandwich" assay, which may also be useful with the antigens of the present invention, the so-called "simultaneous" and "reverse" assays are used. A "simultaneous" assay involves a single incubation step as the antibody bound to the solid support or carrier and labeled antibody are both added to the sample being tested at the same time. After the incubation is completed, the solid support or carrier is washed to remove the residue of fluid sample and uncomplexed labeled antibody. The presence of labeled antibody

associated with the solid support or carrier is then determined as it would be in a conventional "forward" sandwich assay.

In the "reverse" assay, stepwise addition first of a solution of labeled antibody to the fluid sample followed by the addition of unlabeled antibody bound to a solid support or carrier after a suitable incubation period is utilized. After a second incubation, the solid phase is washed in conventional fashion to free it of the residue of the sample being tested and the solution of unreacted labeled antibody. The determination of labeled antibody associated with a solid support or carrier is then determined as in the "simultaneous" and "forward" assays.

The present invention also provides DNA molecules encoding any of the proteins of the present invention as defined above, replicable expression vehicles comprising any such DNA molecules, host cells transformed with any such expression vehicles including prokaryotic and eukaryotic and host cells, preferably CHO cells. The invention also includes a process for the production of expression vectors coding for any of the proteins of the present invention for the purpose of their expression in humans and other mammals.

The invention also includes a process for the production of any of the proteins of the present invention by culturing a transformed cell in accordance with the present invention and recovering the protein encoded by the DNA molecule and the expression vehicle within such transformed host cell.

In addition to the use of an IL-18BP or a viral IL-18BP, in modulating the activity of IL-18, they can, of course, also be employed for the purification of IL-18 itself. For this purpose, IL-18BP or a viral IL-18BP is coupled to an affinity column and crude IL-18 is passed through. The IL-18 can then be recovered from the column by, *e.g.*, elution at low pH.

The invention will now be illustrated by the following non-limiting examples:

EXAMPLE 1: Isolation of an IL-18 binding protein

E. coli IL-18 (2.5 mg, Peprotech, NJ) was coupled to Affigel-10 (0.5 ml, BioRad), according to the manufacturer's instructions and packed into a column. Crude urinary proteins (1000-fold concentrated, 500 ml) were loaded onto the column at a flow rate of 0.25 ml/min. The column was washed with 250 ml 0.5M NaCl in phosphate buffered saline (PBS). Bound proteins were then eluted with 25 mM citric acid, pH 2.2 and benzamidine (1 mM), immediately neutralized by 1M Na₂CO₃. Fractions of 1 ml were collected. The fractions were analyzed by SDS-PAGE and silver staining. The IL-18 binding protein eluted in fractions 2-8 as a ~40,000 Dalton protein (Fig. 1). The ~40 kD band, corresponding to the IL-18BP exhibited a distinct yellow color upon silver staining. The various fractions were analyzed by cross-linking with ¹²⁵I-IL-18, SDS-PAGE and autoradiography as described in Example 2. An IL-18 binding protein was found in fractions 2-8, eluted from the IL-18-agarose column (Fig. 2).

EXAMPLE 2: Cross-linking of affinity-purified IL-18BP to labeled IL-18.

Samples (40 µl) of IL-18BP from the affinity purification step were incubated (70 min. at 4°C) with ¹²⁵I-IL-18 (5,000,000 cpm). Disuccinimidyl suberate (DSS), dissolved in dimethyl sulfoxide (Me₂SO, 20 mM), was then added to a final concentration of 2 mM and the mixture was left for 20 min. at 4°C. The reaction was stopped by the addition of 1M Tris-HCl pH 7.5, and 1M NaCl to a final concentration of 100 mM. A sample buffer containing Dithiothreitol (DTT, 25 mM final) was added and the mixtures were analyzed by SDS-PAGE (7.5 % acrylamide) followed by autoradiography (Fig. 2).

A specific band of molecular weight 58 kD, probably consisting of a ~40 kD protein cross-linked to the ~20 kD ¹²⁵I-IL-18, was observed in fractions eluted from the IL-18 affinity column (lanes 2 and 3) but not in the column wash (lane 1), containing all other crude urinary proteins.

EXAMPLE 3: Protein sequence analysis.

Eluted fractions from the affinity column of Example 1 were resolved by SDS-PAGE (10% acrylamide) under non-reducing conditions, electroblotted on a PVDF membrane (Pro-Blot, Applied Biosystems, USA). The membrane was stained with coomassie blue, the
 5 ~40 kD band was excised and subjected to protein sequence analysis by a Procise microsequencer (Applied Biosystems, USA). The following major sequence was obtained:

T-P-V-S-Q-Q-x-x-x-A-A-A

1 . . . 510 . .

wherein x represents a yet undetermined amino acid.

10 In addition, a minor sequence was obtained:

A-x-Y-x-R-I-P-A-x-A-I-A

1 . . . 510 . .

Because of this double sequence it was not possible to obtain a longer sequence data.
 15 The minor sequence was identified as a fragment of human defensin, (accession No. p11398) starting at amino acid 65 of defensin. The major sequence could not be associated with any other known protein, as determined by searching all available databases in NCBI and TIGR by the blastp and tblastn search programs.

In order to obtain a longer and more accurate sequence and in order to identify
 20 potential cysteine residues, another aliquot of the fraction eluted from the IL-18-agarose column was reduced with DTT in 6 M guanidine HCl, reacted with 4-vinyl pyridine, desalted by a micro-ultrafiltration device (Ultrafree, cutoff 10,000 Daltons, Millipore) and subjected to protein microsequence analysis. After cycle No. 1 of sequencing, the filter was reacted with o-phthalaldehyde to block all N-terminal polypeptides other than Pro. In this way only
 25 the major sequence was obtained as follows:

TPVSQXXXAA XASVRSTKDP CPSQPPVFPA AKQCPALEVT

1 10 20 30 40

30 (T=Thr; P=Pro; V=Val; S=Ser; Q=Gln; X=Unknown; A=Ala; R=Arg; K=Lys; D=Asp; C=Cys; F=Phe; L=Leu; E=Glu)

In cycles 6,7,8 and 11 a low level of a Thr signal was obtained. Because of this low level we considered it more prudent not to assign a specific amino acid residue at said cycles.

The resulting sequence is significantly different from that of any other known protein, as determined by searching protein databases. However, searching the TIGR database by the
 5 tblastn search program provided a cDNA file, denoted THC123801, whose open reading frame (218 codons), when translated contains a sequence highly homologous to that of the N-terminal sequence of IL-18BP. The homology is hereby shown:

```

1  . . . . . TPVSQXXXAAXASVRSTKDPCPSQPPVFPAAKQCPALEVT . . . 40
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
10 51 VTLLVRATXVXQTTTAATASVRSTKDPCPSQPPVFPAAKQCPALEVTWPE 100
  
```

(The upper sequence (1-40) is that of the IL-18BP isolated according to the invention; the lower sequence (51-100) is deduced by translation of the cDNA of TIGR file THC123801).

The putative protein sequence, obtained by translating file THC123801, was
 15 ambiguous at residues 2 and 4 of the IL-18BP. It confirms the identity of amino acid residues 6,7 and 8 of IL-18BP as Thr and seems to do so also for residue 11.

EXAMPLE 4: The IL-18BP is a glycoprotein.

Aliquot (0.3 ml) of eluted fractions of Example 1 were further purified by size
 20 exclusion chromatography on a Superose 12 column (1X30 cm, Pharmacia, Sweden). The column was pre-equilibrated and eluted with phosphate buffered saline and sodium azide (0.02%) at a flow rate of 0.5 ml/min. and fractions of 1 min. were collected. The IL-18 binding protein eluted in fractions 20-25 as a ~40,000 Dalton protein, as determined by SDS-PAGE and silver staining. A sample containing the ~40,000 Dalton protein (fraction
 25 23, 50 µl, ~50 ng protein) was reacted with N-glycosidase F (PNGase F, Biolab) according to the manufacturers instructions. Briefly, the aliquot was denatured by boiling in the presence of 5% SDS for 10 min., 10xG7 buffer (2.5 µl), 10% NP-40 (2.5 µl) and PNGase F (1 µl), 1 h at 37°C. The sample was analyzed by SDS-PAGE (10% acrylamide) under non-reducing conditions and compared with undigested IL-18BP from the same Superose 12 fraction. It was found that the ~40 kD band of IL-18BP disappeared in the PNGase-treated fraction.

New bands, corresponding to 30 kD (just above the PNGase band) and 20 kD were obtained. The elimination of the ~40 kD band indicates that this band is an N-glycosylated protein.

EXAMPLE 5: Blocking of the biological activity of IL-18 by IL-18BP.

The ability of the IL-18BP isolated from urine to block IL-18 activity was determined
5 by measuring the IL-18-induced production of IFN- γ in mononuclear cells. IL-18 induces IFN- γ when added together with either low concentration of LPS, IL-12, IL-2, or other stimulants. The activity of IL-18 was tested in murine splenocytes, in human peripheral blood mononuclear cells (PBMC) and in the human KG-1 cell line. Spleen cells were prepared from a healthy mouse, washed and suspended in RPMI 1640 medium supplemented
10 with 10% fetal bovine serum at 5×10^6 cells/ml. 1.0 ml cultures were stimulated with LPS (either 0.5 or 1 μ g/ml) together with recombinant human or murine IL-18 (either 0.5 or 5 ng/ml). Human IL-18 binding protein (0, 5 or 50 ng/ml) was added to the recombinant IL-18 before adding to spleen cells. After culturing for 24h, the spleen cells were subjected to three freeze (-70°C) and thaw (room temperature) cycles, the cellular debris was removed by
15 centrifugation and the supernatants were assayed for IFN- γ using the ELISA kits for mouse IFN- γ (Endogen). As shown in Fig. 3A, IL-18BP blocked the activity of huIL-18 in murine splenocytes in a dose-dependent manner. In contrast, as a control, soluble interferon- α/β receptor had no effect. The activity of recombinant murine IL-18 was similarly inhibited by the human IL-18BP, suggesting that human IL-18BP recognizes murine IL-18 (Fig. 3B).
20 Endogenous IL-18 is induced in murine splenocytes by high concentrations of LPS, leading to production of IFN- γ . Indeed, IFN- γ induction by LPS (10 μ g/ml) was also inhibited by the urinary IL-18BP (Fig. 3C). Concanavalin A (con A) activates T-cells to produce IFN- γ in the absence of IL-18 (13)]. Indeed, induction of IFN- γ by Con A was not inhibited by IL-18BP even at high concentrations (Fig. 3D). This observation demonstrated that IL-18BP was a
25 specific inhibitor of IL-18 bioactivity rather than a non-specific inhibitor of IFN- γ production. IL-18BP also inhibited the activity of human IL-18 in human KG-1 cells induced by a combination of IL-18 and TNF- α (Fig. 3E).

The above data demonstrate that urinary IL-18BP inhibits human as well as murine IL-18 activity as measured by co-induction of IFN- γ in human and murine mononuclear cells.

The concentration of IL-18BP which reduced IL-18 activity by >90% was comparable to that of IL-18 itself, suggesting a high affinity interaction between these two proteins.

EXAMPLE 6: Isolation of cDNA clones coding for IL-18BP.

Total RNA from Jurkat T-cells (CRL 8163, American Type Culture Collection) was
5 reverse-transcribed with SuperScript RNase H⁻ reverse transcriptase (Gibco-BRL) and
random primers (Promega, Madison WI). The resulting cDNA fragments were then
amplified by PCR, using Taq DNA polymerase (Sigma) and primers corresponding to TIGR
clone THC123801 nucleotides 24-44 (sense) and 500-481 (reverse). The amplification was
done in 30 cycles of annealing (55°C, 2 min) and extension (70°C, 1 min). The resulting
10 PCR products were resolved by agarose (1%) gel electrophoresis, eluted and cloned into
pGEM-Teasy TA cloning vector (Promega). DNA from individual clones was sequenced
with T7 and SP6 primers.

The resulting 477 bp fragment was ³²P-labeled by random priming. This probe was
used for screening various human cDNA and genomic libraries. Duplicate nitrocellulose
15 filters were lifted and hybridized with the probe at 60°C in a buffer consisting of 6xSSC, 10x
Denhardt's solution, 0.1% SDS and 100 µg/ml Salmon sperm DNA. The filters were washed
and exposed overnight at -80°C to Kodak XAR film. Double positive clones were
plaque-purified. Plasmids were excised from the λpCEV9 clones and self-ligated. cDNA
clones from other libraries were isolated according to the manufacturer's instructions.
20 Automated DNA sequence analysis of the isolated clones was performed with Models 373A
and 377 sequencers (Applied Biosystems) using sense and antisense primers. Standard
protocols were used for these cloning procedures (33).

The following libraries were screened: a human monocyte cDNA library, constructed
in λpCEV9 cloning vector (15), kindly provided by T. Miki; a human Jurkat leukemic T-cell
25 cDNA library, a human peripheral blood leukocyte cDNA library and a human spleen cDNA
library, all from Clontech (Palo Alto, CA). A human placenta genomic library in lambda FIX
II vector was from Stratagene (La Jolla, CA).

All cDNA clones corresponded to four different IL-18BP splice variants were
obtained and characterized. All splice variants coded for putative soluble secreted proteins.

The most abundant one (IL-18BP_a) had an open reading frame of 192 codons, coding for a signal peptide of 28 amino acid residues followed by a mature putative IL-18BP_a, whose first 40 residues (SEQ ID NO:10) matched perfectly with the N-terminal protein sequence of the urinary IL-18BP (SEQ ID NO:2). The position of the cysteine residues suggested that this polypeptide belongs to the immunoglobulin (Ig) super-family. Each of the four Gln residues within mature IL-18BP_a was a potential N-glycosylation site. The other three splice variants of IL-18BP were significantly less abundant.

Another 1 kb IL-18BP_b cDNA coded for a mature protein of 85 amino acid residues (SEQ ID NO:4). A third variant, IL-18BP_c, was represented by a 2.3 kb cDNA, coding for a mature IL-18BP of 169 amino acid residues (SEQ ID NO:6). The fourth variant, IL-18BP_d coded for a mature IL-18BP of 133 amino acid residues (SEQ ID NO:8). In-exon splicing occurred at two sites along the pro-mRNA. These events and an additional 5' exon in IL-18BP_d gave rise to 3 different 5' UTRs in the various cDNA clones. It is therefore quite possible that different IL-18BP variants may be generated in response to distinct transcription regulation signals.

No cDNA coding for a receptor with a transmembrane domain was found so far.

Example 7. Construction of a mammalian expression vector, production of recombinant IL-18BP, and evaluation of the biological activities of recombinant IL-18BP

The coding region of the IL-18BP_a cDNA was amplified by PCR with the sense primer 5' TATATCTAGAGCCACCATGAGACACAACCTGGACACCA

and the reverse primer:

5' ATATCTAGATTAATGATGATGATGATGATGACCCTGCTGCTGTGGACTGC.

The PCR products were cut with Xba I and cloned into the Xba I site of the pEF-BOS expression vector (25), to yield pEF-BOS-IL-18BP_a. The constructs were confirmed by DNA sequencing.

Batches of 6×10^7 COS7 cells in 1.4 ml TD buffer, containing pEF-BOS-IL-18BP_a plasmid DNA (10 μ g) and DEAE-dextran (120 μ g) were incubated for 30 min at room

temperature, as described (35). The cells were then washed with DMEM -10% FBS, plated for 4 hr in DMEM-10, washed and incubated for 3-5 days in serum-free DMEM. Culture medium was collected, concentrated 6-fold by ultrafiltration (10 kD cutoff) and the IL-18BP-His₆ was isolated on a Talon column (Clontech) with imidazole as eluant according to the manufacturer's instructions.

Immunological cross-reactivity of the urinary and the COS7-expressed IL-18BP was assessed as follows: Urinary IL-18BP (5 µg) was labeled with ¹²⁵I by the chloramine T procedure. Supernatants of COS7 cells (250 µl) were mixed (1 h, room temperature final volume 500 µl) with the antibody to urinary IL-18BP, diluted 1:1000 in phosphate-buffered saline (PBS), 0.05% Tween 20 and 0.5 % bovine serum albumin (Wash Buffer). ¹²⁵I-labeled urinary IL-18BP (10⁶ cpm) was then added and after 1 h protein G-sepharose (20 µl) was added. The mixture was suspended (1.5 h, 4°C), the beads were then isolated and washed wash 3x Wash Buffer and once in PBS. The beads were then eluted with a Sample buffer, resolved by SDS-PAGE (10% acrylamide under reducing conditions followed by Autoradiography.

IL-18BP_a ran as a single band upon SDS-PAGE with silver staining under reducing and non-reducing conditions and had the same apparent molecular mass as that of the urinary IL-18BP (data not shown). Protein sequence analysis of this preparation revealed the same N-terminal sequence as that of the urinary IL-18BP, indicating that the latter was not degraded at its N-terminus.

Immunoblot analysis of IL-18BP_a with antibodies raised against the urinary IL-18BP revealed the same molecular mass band as that of the urinary protein. Furthermore, using immunoprecipitation followed by SDS-PAGE and autoradiography, IL-18BP_a was able to displace urinary ¹²⁵I-IL-18BP from binding to the antibody. Therefore, IL-18BP_a corresponds structurally to the urinary IL-18BP.

Crude and purified IL-18BP_a was tested for its ability to inhibit the biological activity of IL-18. IL-18BP_a inhibited in a dose dependent manner the IFN-γ inducing activity of human and mouse IL-18 in murine splenocytes, PBMC and the human KG-1 cell line (Fig. 9).

The results of the various bioassays as well as the mobility shift assay (Example 8) demonstrated that inhibition of IL-18 activity is an intrinsic property of the cloned IL-18BP and not that of any accompanying impurities in urinary IL-18BP, such as the co-eluting fragment of defensin.

5 **Example 8. Electrophoretic mobility shift assays**

The effect of the urinary and the recombinant IL-18BP on IL-18-induced activation of NF- κ B in human KG-1 cells was also studied. Human KG-1 cells (4×10^6 in 1 ml RMPI) were stimulated with either huIL-18 (10 ng/ml) or huIL-18 pre-mixed with an IL-18BP (20 min, room temperature). After 20 min at 37°C, cells were washed three times with ice-cold
10 PBS and immediately frozen in liquid nitrogen. Cell pellets were resuspended in three times the packed cell volume in buffer A (20 mM Tris pH 7.6, 0.4M NaCl, 0.2 mM EDTA, glycerol (20% by volume), 1.5 mM MgCl₂, 2 mM dithiothreitol (DDT), 0.4 mM PMSF, 1 mM Na₃VO₄, 2 μ g/ml each of leupeptin, pepstatin and aprotinin). Cell debris was removed by centrifugation (15,000xg, 15 min.), aliquots of the supernatant were frozen in liquid nitrogen
15 and stored at -80°C. Protein concentration was determined by a Bradford assay (Bio-Rad) using bovine serum albumin as standard. A double-stranded oligonucleotide corresponding to NF- κ B binding element (10 pmol, Promega) was labeled with [³²P]dCTP (300 Ci/mmol) and T4 polynucleotide kinase (New England Biolabs). Free nucleotides were removed by a spin column. Extracts (10 μ g protein) of cells treated with IL-18 or IL-18 plus IL-18BP were
20 incubated (15 min., room temperature) with the labeled probe (3×10^4 cpm) together with poly dI.dC (500 ng, Pharmacia) and denatured salmon sperm DNA (100 ng, Sigma) in 20 μ l buffer consisting of HEPES (pH 7.5, 10 mM), 60 mM KCl, 1 mM MgCl₂, 2 mM EDTA, 1 mM DTT and glycerol (5% by volume). The mixtures were then loaded onto 5% non-denaturing polyacrylamide gels. Electrophoresis was performed at 185 V in 0.5xTBE
25 (40 mM Tris HCl, 45 mM boric acid and 2.5 mM EDTA). Gels were vacuum dried and autoradiographed overnight at -80°C. IL-18 was found to induce the formation of the p50 NF- κ B homodimer and the p65/p50 NF- κ B heterodimer. Urinary as well as recombinant IL-18BP inhibited the activation of NF- κ B by IL-18, as determined by an electrophoretic mobility shift assay with KG-1 cell extracts binding a radiolabeled oligonucleotide
30 corresponding to the NF- κ B consensus sequence.

Example 9. Expression of IL-18BP in *E. coli*, yeast and insect cells.

IL-18BP may also be produced by other recombinant cells such as prokaryotic cells, *e.g.*, *E. coli*, or other eukaryotic cells, such as yeast and insect cells. Well known methods are available for constructing appropriate vectors, carrying DNA that codes for either IL-18BP and suitable for transforming *E. coli* and yeast cells, or infecting insect cells in order to produce recombinant IL-18BP. For expression in yeast cells, the DNA coding for IL-18BP (Example 6) is cut out and inserted into expression vectors suitable for transfection of yeast cells. For expression in insect cells, a DNA coding for IL-18BP is inserted into baculovirus and the insect cells are infected with said recombinant baculovirus. For expression in *E. coli*, the DNA coding for IL-18BP is subjected to site directed mutagenesis with appropriate oligonucleotides, so that an initiation ATG codon is inserted just prior to the first codon of mature IL-18BP. Alternatively, such DNA can be prepared by PCR with suitable sense and antisense primers. The resulting cDNA constructs are then inserted into appropriately constructed prokaryotic expression vectors by techniques well known in the art (23).

Example 10: Construction of adeno-associated expression vector for in vivo expression of IL-18BP_a

A functional gene coding for IL-18BP_a is constructed based on plasmid pcDNA3 (Invitrogen, San Diego CA). The IL-18BP cDNA with a Kozak consensus sequence at the 5' end is ligated into the Xba I site of pcDNA3 in a way that destroys the restriction site. New Xba I sites are inserted by site-directed mutagenesis before the neomycin cassette (base 2151 of the original pcDNA3 sequence) and after the SV40 polyadenylation signal (base 3372 of the original pcDNA3 sequence). This construct is then cut with Xba I and the resulting 4.7 kb minigen is inserted at the Xba I site of plasmid psub201 as described (Snyder et al, 1996, Current Protocols in Human Genetics, Chapters 12.1.1-12.1.17, John Wiley & Sons). The resulting recombinant plasmid is cotransfected with the helper AAV plasmid pAAV/Ad into human T293 cells. The cultures are then infected with adenovirus as a helper virus and the cells are collected after 48-60 hours of incubation. The cells are subjected to 3 freeze-thaw cycles, cell debris is removed by centrifugation, and the supernatant is brought to 33% saturation with ammonium sulfate. The mixture is then centrifuged and rAAV is precipitated from the supernatant by bringing the ammonium sulfate to 50% saturation. The virus is

further purified by CsCl, dialyzed and finally heated for 15 min at 56°C to destroy any adenovirus.

Example 11: Construction of recombinant fusion proteins of IL-18BP

The production of proteins comprising IL-18BP fused to the constant region of IgG2 heavy chain may be carried out as follows: the DNA of IL-18BP is subjected to site-directed mutagenesis with appropriate oligonucleotides so that a unique restriction site is introduced immediately before and after the coding sequences. A plasmid bearing the constant region of IgG2 heavy chain, *e.g.* pRKCO42Fc1(6) is subjected to similar site-directed mutagenesis to introduce the same unique restriction site as close as possible to Asp 216 of IgG1 heavy chain in a way that allows translation in phase of the fused protein. A dsDNA fragment, consisting of 5' non-translated sequences and encoding for IL-18BP is prepared by digestion at the unique restriction sites or alternatively by PCR with appropriately designed primers. The mutated pRKCD42Fc1 is similarly digested to generate a large fragment containing the plasmid and the IgG1 sequences. The two fragments are then ligated to generate a new plasmid, encoding a polypeptide precursor consisting of IL-18BP and about 227 C-terminal amino acids of IgG1 heavy chain (hinge region and CH2 and CH3 domains). The DNA encoding the fused proteins may be isolated from the plasmid by digestion with appropriate restriction enzymes and then inserted into efficient prokaryotic or eukaryotic expression vectors.

Example 12 : Production of chemically modified IL-18BPs

In order to increase the half-life of the IL-18BPs in plasma, IL-18BPs which are chemically modified with polyethylene glycol (PEG) may be made. The modification may be done by cross linking PEG to a cysteine residue of the IL-18BP molecules. Mutant IL-18BPs may be constructed which contain an extra cysteine residue at the amino terminus, glycosylation sites, and the carboxyl terminus of each IL-18BP. The mutagenesis may be carried out by PCR using oligonucleotides containing the desired mutation. These mutant

proteins are expressed in the usual manner as well known in the art. Pegylation of these proteins will be carried out and the activity will be assessed.

Example 13: Preparation of polyclonal antibodies to IL-18BP

Rabbits were initially injected subcutaneously with 5 µg of a pure preparation of the urinary IL-18BP, emulsified in complete Freund's adjuvant. Three weeks later, they were injected again subcutaneously with 5 µg of the IL-18BP preparation in incomplete Freund's adjuvant. Two additional injections of IL-18BP as solution in PBS were given at 10 day intervals. The rabbits were bled 10 days after the last immunization. The development of antibody level was followed by a radioimmunoassay. ¹²⁵I-labeled IL-18BP (166,000 cpm) was mixed with various dilutions (1:50, 1:500, 1:5,000 and 1:50,000) of the rabbit serum. A suspension of protein-G agarose beads (20 µl, Pharmacia) was added in a total volume of 200 µl. The mixture was left for 1 hour at room temperature, the beads were then washed 3 times and bound radioactivity was counted. Rabbit antiserum to human leptin was used as a negative control. The titer of the IL-18R antiserum was between 1:500 and 1:5000, while that of the negative control was less than 1:50.

EXAMPLE 14: Preparation of monoclonal antibodies to IL-18BP

Female Balb/C mice (3 months old) are first injected with 2 µg purified IL-18BP in an emulsion of complete Freund's adjuvant, and three weeks later, subcutaneously in incomplete Freund's adjuvant. Three additional injections are given at 10 day intervals, subcutaneously in PBS. Final boosts are given intraperitoneally 4 and 3 days before the fusion to the mouse showing the highest binding titer as determined by IRIA (see below). Fusion is performed using NSO/1 myeloma cell line and lymphocytes prepared from both the spleen and lymph nodes of the animal as fusion partners. The fused cells are distributed into microculture plates and the hybridomas are selected in DMEM supplemented with HAT and 15% horse serum. Hybridomas that are found to produce antibodies to IL-18BP are subcloned by the limiting dilution method and injected into Balb/C mice that had been primed with pristane for the production of ascites. The isotypes of the antibodies are defined with the use of a commercially available ELISA kit (Amersham, UK).

The screening of hybridomas producing anti-IL-18BP monoclonal antibodies is performed as follows: Hybridoma supernatants are tested for the presence of anti-IL-18BP antibodies by an inverted solid phase radioimmunoassay (IRIA). ELISA plates (Dynatech Laboratories, Alexandria, VA) are coated with Talon-purified IL-18BP_a-His₆ (10 µg/ml, 100 µl/well). Following overnight incubation at 4°C, the plates are washed twice with PBS containing BSA (0.5%) and Tween 20 (0.05%) and blocked in washing solution for at least 2 hrs at 37°C. Hybridoma culture supernatants (100 µl/well) are added and the plates are incubated for 4 hrs at 37°C. The plates are washed 3 times and a conjugate of goat-anti-mouse horseradish peroxidase (HRP, Jackson Labs, 1:10,000, 100 µl/well) is added for 2 hrs at room temperature. The plates are washed 4 times and the color is developed by ABTS (2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid, Sigma) with H₂O₂ as a substrate. The plates are read by an automatic ELISA reader. Samples giving OD that are at least 5 times higher than the negative control value are considered positive.

EXAMPLE 15: Affinity chromatography of IL-18BP with monoclonal antibodies

Antibodies against IL-18BP are utilized for the purification of IL-18BP by affinity chromatography. Ascitic fluid containing the monoclonal antibody secreted by the hybridoma is purified by ammonium sulfate precipitation at 50% saturation followed by extensive dialysis against PBS. About 10 mg of immunoglobulins are bound to 1 ml Affigel 10 (BioRad USA), as specified by the manufacturer.

250 ml of human urinary proteins (equivalent to 250 l of crude urine) are loaded on 0.5 ml of the anti IL-18BP antibody column at 4°C at a flow rate of 0.25 ml/min. The column is washed with PBS until no protein is detected in the washings. IL-18BP is eluted by 25 mM citric acid buffer, pH 2.2 (8 x 1 column volume fractions) and immediately neutralized by 1 M Na₂CO₃. Further purification of this preparation is obtained by size exclusion chromatography.

EXAMPLE 16: ELISA test

Microtiter plates (Dynatech or Maxisorb, by Nunc) are coated with anti-IL-18BP monoclonal antibody (serum free hybridoma supernatant or ascitic fluid immunoglobulins) overnight at 4°C. The plates are washed with PBS containing BSA (0.5%) and Tween 20 (0.05%) and blocked in the same solution for at least 2 hrs at 37°C. The tested samples are diluted in the blocking solution and added to the wells (100 µl/well) for 4 hrs at 37°C. The plates are then washed 3 times with PBS containing Tween 20 (0.05%) followed by the addition of rabbit anti-IL-18BP serum (1:1000, 100 µl/well) for further incubation overnight at 4°C. The plates are washed 3 times and a conjugate of goat-anti-rabbit horseradish peroxidase (HRP, Jackson Labs, 1:10,000, 100 µl/well) was added for 2 hrs at room temperature. The plates were washed 4 times and the color is developed by ABTS (2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid, Sigma) with H₂O₂ as a substrate. The plates are read by an automatic ELISA reader.

EXAMPLE 17 : Non-glycosylated human IL-18BP is biologically active.

Purified recombinant IL-18BP_a was tested for its ability to inhibit the biological activity of IL-18. IL-18BP_a inhibited in a dose dependent manner the IFN-γ inducing activity of human and mouse IL-18 in murine splenocytes, PBMC and the human KG-1 cell line (Fig. 9).

Purified IL-18BP_a having an His₆ tag at the C-terminus (1.5 µg, 50 µl) was adjusted to pH 7.5 and mixed with N-glycosidase F (3 µl, 500,000 U/ml, PNGase F, New England Biolabs). The mixture was incubated for 24 h at 37°C under non-denaturing conditions. Aliquots from the sample and from undigested IL-18BP-His₆ were analyzed by SDS-PAGE under non-reducing conditions followed by immunoblotting with antibodies to IL-18PB. It was found that the ~40 kD band of IL-18BP-His₆ disappeared in the PNGase-treated fraction and a new ~20 kD band was obtained. The molecular mass of the product and the specificity of PNGase F indicated that IL-18BP-His₆ was fully deglycosylated.

The PNGase-treated fraction, undigested IL-18BP-His₆ and control sample containing PNGase in buffer were absorbed separately on Talon beads, washed with phosphate buffer and eluted with imidazole (100 mM). The eluted fractions were subjected to bioassay using human IL-18 (20 ng/ml), LPS (2 µg/ml) and murine splenocytes. The results are shown in the following table:

<u>Sample</u>	<u>IFN-γ (ng/ml)</u>
Control	7.5
Non-digested IL-18BP-His ₆	0
PNGase-treated IL-18BP-His ₆	0

Therefore, it is concluded that deglycosylated IL-18BP is biologically active as a modulator of IL-18 activity.

The foregoing description of the specific embodiments reveal the general nature of the invention so that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation.

References

1. **Anderson, D.M., et al.,** *A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.* *Nature*, 1997. **390**(6656): p. 175-179.
2. **Bollon, D. P., et al.** (1980) *J. Clin. Hematol. Oncol.* **10**:39-48.
- 5 3. **Botstein, D., et al.** (1982) *Miami Wint. Symp.* **19**:265-274.
4. **Broach, J. R.,** in "The Molecular Biology of the Yeast *Saccharomyces*: Life Cycle and Inheritance", Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 445-470 (1981).
5. **Broach, J. R.,** (1982) *Cell* **28**:203-204.
- 10 6. **Byrn R. A. et al.,** 1990, *Nature* (London) **344**:667-670.
7. **Car, B. D., V. M. Eng, B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Aguet, and B. Ryffel.** 1994. Interferon gamma receptor deficient mice are resistant to endotoxic shock. *J. Exp. Med.* **179**:1437-44 issn: 0022-1007.
8. **Chater, K. F. et al.,** in "Sixth International Symposium on Actinomycetales
15 Biology", Akademiai Kaido, Budapest, Hungary (1986), pp. 45-54).
9. **Conti, B., J. W. Jahng, C. Tinti, J. H. Son, and T. H. Joh.** 1997. Induction of interferon-gamma inducing factor in the adrenal cortex. *J. Biol. Chem.* **272**:2035-2037.
10. **Dao, T., K. Ohashi, T. Kayano, M. Kurimoto, and H. Okamura.** 1996. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated
20 cytotoxicity of murine T helper 1 cells. *Cell-Immunol.* **173**:230-5 issn: 0008-8749.
11. **Engelmann, H., D. Aderka, M. Rubinstein, D. Rotman, and D. Wallach.** 1989. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. *J. Biol. Chem.* **264**:11974-11980.

12. **Engelmann, H., D. Novick, and D. Wallach.** 1990. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. *J. Biol. Chem.* **265**:1531-1536.
- 5 13. **Fantuzzi, G., et al.,** *IL-18 regulation of IFN-g production and cell proliferation as revealed in interleukin-1b converting enzyme-deficient mice.* *Blood*, 1998. **91**: p. 2118-2125.
14. **Gryczan, T.,** "The Molecular Biology of the Bacilli", Academic Press, NY (1982), pp. 307-329).
- 10 15. **Gutkind, J.S., et al.,** *A novel c-fgr exon utilized in Epstein-Barr virus-infected B lymphocytes but not in normal monocytes.* *Molec. Cell. Biol.*, 1991. **11**: p. 1500-1507.
16. **Heremans, H., J. Van Damme, C. Dillen, R. Dijkmans, and A. Billiau.** 1990. Interferon gamma, a mediator of lethal lipopolysaccharide-induced Schwartzman-like shock reactions in mice. *J. Exp. Med.* **171**:1853-69 issn: 0022-1007.
- 15 17. **Izaki, K.** (1978) *Jpn. J. Bacteriol.* **33**:729-742).
18. **John, J. F., et al.** (1986) *Rev. Infect. Dis.* **8**:693-704).
19. **Kendall, K. J. et al.** (1987) *J. Bacteriol.* **169**:4177-4183).
20. **Kohno, K., J. Kataoka, T. Ohtsuki, Y. Suemoto, I. Okamoto, M. Usui, M. Ikeda, and M. Kurimoto.** 1997. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the
20 activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. *J. Immunol.* **158**:1541-1550.
21. **Maliszewski, C. R., T. A. Sato, T. Vanden Bos, S. Waugh, S. K. Dower, J. Slack, M. P. Beckmann, and K. H. Grabstein.** 1990. Cytokine receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-1- and IL-4-induced B cell activities in
25 vitro. *J. Immunol.* **144**:3028-3033.

22. **Maniatis, T.**, in "Cell Biology: A Comprehensive Treatise, Vol. 3: Gene Expression", Academic Press, NY, pp. 563-608 (1980).
23. **Maniatis et al.**, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1982.
- 5 24. **Micallef, M. J., T. Ohtsuki, K. Kohno, F. Tanabe, S. Ushio, M. Namba, T. Tanimoto, K. Torigoe, M. Fujii, M. Ikeda, S. Fukuda, and M. Kurimoto.** 1996. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. *Eur-J-Immunol* **26**:1647-51 issn: 0014-2980.
- 10 25. **Mizushima, S. and Nagata, S.** (1990) pEF-BOS, a powerful mammalian expression vector. *Nucleic Acid Res.* **18**:5322-5328.
26. **Nakamura, K., H. Okamura, K. Nagata, T. Komatsu, and T. Tamura.** 1993. Purification of a factor which provides a costimulatory signal for gamma interferon production. *Infect-Immun* **61**:64-70 issn: 0019-9567.
- 15 27. **Nakamura, K., H. Okamura, M. Wada, K. Nagata, and T. Tamura.** 1989. Endotoxin-induced serum factor that stimulates gamma interferon production. *Infect-Immun* **57**:590-5 issn: 0019-9567.
28. **Novick, D., B. Cohen, and M. Rubinstein.** 1994. The Human Interferon alpha/beta Receptor - Characterization and Molecular Cloning. *Cell* **77**:391-400.
- 20 29. **Novick, D., B. Cohen, and M. Rubinstein.** 1992. Soluble Interferon-alpha Receptor Molecules Are Present in Body Fluids. *FEBS Lett* **314**:445-448.
30. **Novick, D., H. Engelmann, D. Wallach, and M. Rubinstein.** 1989. Soluble cytokine receptors are present in normal human urine. *J. Exp. Med.* **170**:1409-1414.
- 25 31. **Okamura, H., H. Tsutsui, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, K. Akita, M. Namba, F. Tanabe, K. Konishi,**

S. Fukuda, and M. Kurimoto. 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. *Nature* **378**:88-91.

32. **Rothe, H., N. A. Jenkins, N. G. Copeland, and H. Kolb.** 1997. Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. *J-Clin-Invest* **99**:469-74 issn: 0021-9738.

33. **Sambrook, J., E.F. Fritsch, and M. T.,** *Molecular Cloning: A laboratory manual.* 2nd ed. ed. 1989, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory.

34. **Simonet, W.S., et al.,** *Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.* *Cell*, 1997. **89**(2): p. 309-319.

35. **Sompayrac, L.H. and K.L. Danna,** *Efficient infection of monkey cells with DNA of simian virus 40.* *Proc. Nat'l. Acad. Sci. USA*, 1981. **78**: p. 7575-7578.

36. **Sparks, C.A., et al.,** *Assignment of the nuclear mitotic apparatus protein NuMA gene to human chromosome 11q13.* *Genomics*, 1993. **17**: p. 222-224.

37. **Tsutsui, H., K. Nakanishi, K. Matsui, K. Higashino, H. Okamura, Y. Miyazawa, and K. Kaneda.** 1996. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. *J. Immunol.* **157**:3967-73 issn: 0022-1767.

38. **Ushio, S., M. Namba, T. Okura, K. Hattori, Y. Nukada, K. Akita, F. Tanabe, K. Konishi, M. Micallef, M. Fujii, K. Torigoe, T. Tanimoto, S. Fukuda, M. Ikeda, H. Okamura, and M. Kurimoto.** 1996. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in *Escherichia coli*, and studies on the biologic activities of the protein. *J. Immunol.* **156**:4274-4279. 34. Okayama, H. and Berg, P. (1983) A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells. *Mol. Cell. Biol.* **3**:280-289.

39. **Yasuda, H., et al.,** *Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.* *Endocrinology*, 1998. **139**: p. 1329-1337.

SEQUENCE LISTING

<110> Novick, Daniela
 Dinarello, Charles
 Rubinstein, Menachem
 Kim, Soo Hyun
 Yeda Research and Development Co. Ltd.

<120> Interleukin-18 Binding Proteins, their Preparation and Use

<130> IL-18 Rubinstein

<140>
 <141>

<150> 125463
 <151> 1998-07-22

<150> 122134
 <151> 1997-11-06

<150> 121869
 <151> 1997-09-29

<150> 121639
 <151> 1997-08-27

<150> 121554
 <151> 1997-08-14

<160> 10

<170> PatentIn Ver. 2.0

<210> 1
 <211> 1348
 <212> DNA
 <213> Homo sapiens

<400> 1
 gagaagagga cggtgtcaca gataaagagc caggctcacc agctcctgac gcatgcatca 60
 tgaccatgag acacaactgg acaccagacc tcagcccttt gtgggtcctg ctctgtgtg 120
 cccacgtcgt cactctctg gtcagagcca cacctgtctc gcagaccacc acagctgcc 180
 ctgcctcagt tagaagcaca aaggaccctt gcccctccca gcccacagt ttcccagcag 240
 ctaagcagtg tccagcattg gaagtgcact ggccagaggt ggaagtgcc ctgaatggaa 300
 cgctgagctt atcctgtgtg gcctgcagcc gcttcccaa cttcagcatc ctctactggc 360
 tgggcaatgg ttccttcatt ggcacctcc caggccgact gtgggagggg agcaccagcc 420

```

gggaacgtgg gagcacaggt acgcagctgt gcaaggcctt ggtgctggag cagctgaccc 480
ctgccctgca cagcaccaac ttctcctgtg tgctcgtgga ccctgaacag gttgtccagc 540
gtcacgtcgt cctggcccag ctctgggctg ggctgagggc aaccttgccc cccacccaag 600
aagccctgcc ctccagccac agcagtccac agcagcaggg ttaagactca gcacagggcc 660
agcagcagca caaccttgac cagagcttgg gtcctacctg tctacctgga gtgaacagtc 720
cctgactgcc tgtaggctgc gtggatgcgc aacacacccc ctcttctctt gctttgggtc 780
ccttctctca ccaaattcaa actccattcc cacctacctt gaaaatcaca gcctccctat 840
aatgcctcct cctcctgcca ttctctctcc acctatccat tagccttctt aacgtcctac 900
tcctcacact gctctactgc tcagaaacca ccaagactgt tgatgcctta gccttgcact 960
ccagggccct acctgcattt cccacatgac tttctggaag cctcccaact attcttgctt 1020
ttcccagaca gctccactc ccattgtctt gctcatttag tcccgctctt ctcaccgccc 1080
cagcagggga acgctcaagc ctggttgaaa tgctgcctct tcagtgaagt catcctcttt 1140
cagctctggc cgcattctgc agacttccta tcttcgtgct gtagtgtttt tttttccccc 1200
ttcactctaa tggactgttc caggaagggt atggggggcac cagctgcttc ggatccacac 1260
tgtatctgtg tcatccccc atgggtcctc ataaaggatt attcaatgga aaaaaaaaaa 1320
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1348

```

<210> 2

<211> 192

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> (1)..(28)

<400> 2

```

Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val Leu Leu
  1              5              10              15

```

```

Leu Cys Ala His Val Val Thr Leu Leu Val Arg Ala Thr Pro Val Ser
          20              25              30

```

```

Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys Asp Pro
      35              40              45

```

```

Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys Pro Ala
      50              55              60

```

```

Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Asn Gly Thr Leu
      65              70              75              80

```

```

Ser Leu Ser Cys Val Ala Cys Ser Arg Phe Pro Asn Phe Ser Ile Leu
          85              90              95

```

```

Tyr Trp Leu Gly Asn Gly Ser Phe Ile Glu His Leu Pro Gly Arg Leu
          100              105              110

```

Trp Glu Gly Ser Thr Ser Arg Glu Arg Gly Ser Thr Gly Thr Gln Leu
 115 120 125
 Cys Lys Ala Leu Val Leu Glu Gln Leu Thr Pro Ala Leu His Ser Thr
 130 135 140
 Asn Phe Ser Cys Val Leu Val Asp Pro Glu Gln Val Val Gln Arg His
 145 150 155 160
 Val Val Leu Ala Gln Leu Trp Ala Gly Leu Arg Ala Thr Leu Pro Pro
 165 170 175
 Thr Gln Glu Ala Leu Pro Ser Ser His Ser Ser Pro Gln Gln Gln Gly
 180 185 190

<210> 3
 <211> 1038
 <212> DNA
 <213> Homo sapiens

<400> 3
 gagaagagga cggtgtcaca gataaagagc caggctcacc agctcctgac gcatgcatca 60
 tgaccatgag acacaactgg acaccagacc tcagcccttt gtgggtcctg ctccctgtgtg 120
 cccacgtcgt cactctcctg gtcagagcca cacctgtctc gcagaccacc acagctgccca 180
 ctgcctcagt tagaagcaca aaggaccctt gcccttccca gccccagtg ttcccagcag 240
 ctaagcagtg tccagcattg gaagtgcctt ggccagaggt ggaagtgccca ctgagctggg 300
 ctgaggggcaa ccttgccccc cacccaagaa gccttgccct ccagccacag cagtccacag 360
 cagcagggtt aagactcagc acagggccag cagcagcaca accttgacca gagcttgggt 420
 cctacctgtc tacctggagt gaacagtcct tgactgcctg taggctgcgt ggatgcgcaa 480
 cacacccctt ccttctctgc tttgggtccc ttctctcacc aaattcaaac tccattccca 540
 cctacctaga aaatcacagc ctccattataa tgctctctcc tcttgccatt ctctctccac 600
 ctatccatta gccttccctaa cgtccctact ctcacactgc tctactgtc agaaaccacc 660
 aagactgttg atgccttagc cttgcactcc agggccctac ctgcatttcc cacatgactt 720
 tctggaagcc tcccaactat tcttgctttt cccagacagc tcccactccc atgtctctgc 780
 tcatttagtc ccgtcttctt caccgccccca gcagggggaa gctcaagcct ggttgaaatg 840
 ctgcctcttc agtgaagtca tcctctttca gctctggccg cattctgcag acttcctatc 900
 ttctgtctgt atgttttttt ttccccctt cactctaagt gactgttcca gggaagggat 960
 gggggcacca gctgcttcgg atccacactg tatctgtgtc atccccacat gggctcctcat 1020
 aaaggattat tcaatgga 1038

<210> 4
 <211> 113
 <212> PRT
 <213> Homo sapiens

<220>

<221> SIGNAL

<222> (1)..(28)

<400> 4

Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val Leu Leu
 1 5 10 15

Leu Cys Ala His Val Val Thr Leu Leu Val Arg Ala Thr Pro Val Ser
 20 25 30

Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys Asp Pro
 35 40 45

Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys Pro Ala
 50 55 60

Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Ser Trp Ala Glu
 65 70 75 80

Gly Asn Leu Ala Pro His Pro Arg Ser Pro Ala Leu Gln Pro Gln Gln
 85 90 95

Ser Thr Ala Ala Gly Leu Arg Leu Ser Thr Gly Pro Ala Ala Ala Gln
 100 105 110

Pro

<210> 5

<211> 7063

<212> DNA

<213> Homo sapiens

<400> 5

gaattcgcg cgcgctcgac gccagagggg ctaggatgag agacagaggg tgtgatgggtg 60
 ggtgctggga aatgtacccg accttggggc tgggtggctgg gggagtgggt agcctgggaa 120
 aggccaggat gtggacggac tggatatggca ttgagcctga agtgggtccaa cttgggggttc 180
 cccagtgcct aggaaagtgt tccccttgaa tgtcagtgtg aagggtgaagg aggaagcaga 240
 tgcctgttca tatggaaaca aagacctggc tgtgaagagg ggaggcggac accaaagtcc 300
 tgacacttgg gcgggacaga attgatctgt gagagactca tctagttcat accctaggtg 360
 accctggggg tggcatgggg gtagattaga gatcccagtc tggatatcctc tggagagtag 420
 gagtcccagg agctgaaggt ttctggccac tgaactttgg ctaaagcaga ggtgtcacag 480
 ctgctcaaga ttccctgggt aaaaagtga agtgaaatag agggtcgggg cagtgccttc 540
 ccagaaggat tgctcgcat cctgcccttc ccagaagcag ctctggtgct gaagagagca 600
 ctgcctccct gtgtgactgg gtgagtccat attctctctt tgggtctcaa ttttgccttc 660

```

cctaataaag gggtaagatt ggactaggta agcatcttac aaccatttgt ggcatgaga 720
gctgggggtgg ggaaggattg tcaactgacc cccccagctc tgtttctaag tgctgaaaga 780
gctccagggt atgctacggg aggagaagcc agctactgag gaaaagccag ctactgagaa 840
aaagcggggag tggtttacca ttctctctcc ccacctttca ccagagaaga ggacgttgtc 900
acacataaag agccaggctc accagctcct gacgcatgca tcatgaccat gagacacaac 960
tggacaccag acctcagccc tttgtgggtc ctgctcctgt gtgcccacgt cgtcactctc 1020
ctggtcagag ccacacctgt ctgcagacc accacagctg ccaactgcctc agttagaagc 1080
acaaaggacc cctgccccctc ccagcccccag gtgttcccag cagctaagca gtgtccagca 1140
ttggaagtga cctggccaga ggtggaagtg ccactgaatg gaacgctgag cttatcctgt 1200
gtggcctgca gccgcttccc caacttcagc atcctctact ggctgggcaa tggttccttc 1260
attgagcacc tcccaggccg actgtgggag gggagcacca gccgggaacg tgggagcaca 1320
ggtacgcagc tgtgcaaggc cttggtgctg gagcagctga cccctgccct gcacagcacc 1380
aacttctcct gtgtgctcgt ggaccctgaa caggttgtcc agcgtcacgt cgtcctggcc 1440
cagctctggg tgaggagccc aaggagaggc ctccaggaac aggaggagct ctgcttccat 1500
atgtggggag gaaaggggtg gctctgccag agcagcctgt gaactaatgc ccagcatcc 1560
tcaaggtcag ccagacaaaa aggaacttag gtcttgggca gaggaggtgt agcctggggc 1620
aaagtgatga gatgtccctc ctttctctgg cctgctcctt gtctgccttc acttccctag 1680
gctgggctga gggcaacctt gccccccacc caagaagccc tgccctccag ccacagcagt 1740
ccacagcagc agggttaaga ctcagcacag ggccagcagc agcacaacct tgaccagagc 1800
ttgggtccta cctgtctacc tggagtgaac agtccctgac tgctgttagg ctgctggat 1860
gcgcaacaca cccctcctt ctctgctttg ggtcccttct ctaccaaact tcaaactcca 1920
ttccaccta cctagaaaat cacagcctcc ttataatgcc tctcctcct gccattctct 1980
ctccacctat ccattagcct tccaaacgtc ctactcctca cactgctcta ctgctcagaa 2040
accaccaaga ctgttgatgc cttagccttg cactccaggg ccctacctgc atttcccaca 2100
tgactttctg gaagcctccc aactattctt gcttttccca gacagctccc actcccatgt 2160
ctctgctcat ttagtccctg ctctctcacc gcccagcag gggaaacgctc aagcctggtt 2220
gaaatgctgc ctcttcagtg aagtcactct ctttcagctc tggccgcatt ctgcagactt 2280
cctatctctg tgcgtatgt ttttttttcc ccccttccct ctaatggact gttccaggga 2340
agggatgggg gcagcagctg cttcggatcc aactgtatc tgtgtcatcc ccacatgggt 2400
cctcataaag gattattcaa tggaggcatc ctgacatctg ttcatctagg cttcagttcc 2460
actcccagga actttgcctg tcccacgagg gagtatggga gagatggact gccacacaga 2520
agctgaagac aacacctgct tcagggggaa acaggcgctt gaaaaagaaa agagagaaca 2580
gcccataatg ctccccggga gcagaggcca ctaatggaga gtgggaagag cctggaaaaga 2640
tgtggcctca ggaaaaggga tgagagaaaag gaggtggtat ggaagactca gcaggaacaa 2700
ggtaggcctc aaagagccta tattcctctt tttccacac cgatcaagtc aactcagtac 2760
tcacgggaga aaaatagact ttatttacaa gtaataacat ttagaaaaga tccatccccg 2820
gcccctaaaa accttcccat cactccaaat cccacccag tgcaagtctg gggaaggtag 2880
ggtgtgagct gctgctgaag gctgtcccc aacccactc ctgagacaca gggcccatcc 2940
gtcctgggaa agagcatcct ctggcaggtg ctcccaccag gtcagacca gtctggact 3000
tcaagagtga gggccctgct tgggcccagc caccaggaca gcaggaacca gggcctactc 3060
ctcttatggt ccttctctaga tccagaggct aagagggaaga ctggccaggc ccaaggacct 3120
agccatcaaa accagcctca aatctggttg tgatggagaa gtgactttgc tttaagaaaa 3180
aaggaggcaa ggtagggaga gcgcccacac tgtccatgct ccaggcccc tgggcccagct 3240
ccgagaaggc gccagtgaag gaccagggac caggccaggg tgcgggcagg catcactgtc 3300
tctagggtt tggctactgt tggcctggga gctgagagaa ggcactgaga gggacagtag 3360
gcggaggacc aggtgacggc agcatcgggg acacaggtgg ggccactcac tggtagtggc 3420
cctttagtgct tttgcctgaa agagacacag tcacatggcc agatgagaac ttgcgatact 3480
agcctgcacc cactggctgg gaagatctct tctgctccc acgcccctgt ctggatcccc 3540

```

```

tcccttgtga gccccagggg tatcagttgc tggctgtgcc tgagcagctc tgggtgtctc 3600
ccatgagaat ggggccatct gtcttctctc cttggagagg agctaccagg acagggacac 3660
ctcttaccac acacctccca gcagcctggc gtggcccat cttggatgct acttgggtggg 3720
gcggtctggg ggggtgccat gctctcatcg ggtttccctc cccatcctg ccagtgcctc 3780
taccttgccc ttggctcgag ggggtggacc aatggcggca gcagtggcgg cgctggctgt 3840
gggtgggtggca atgcgcggag aacggcgggt tccactgcga gtgttggggg aagccttggg 3900
cagggccttc tttgaggctc cccgcgcgag aaggctgttc cctagcttct tgggtgtgtt 3960
gaggatgctg aaggccatcg actggcgccg gtcagcctgc aaggaagggc tgtcagaccg 4020
ggagacccaa tgctgccttc ccaggccagc gtgctgtgcc acgctgtacc agcaaggtcc 4080
cgccaggggc tcgcttcctc ccccttcagc cccagcctca cctgtttagt agaagctgga 4140
gctgctttct tctgggcctc agtagtgctc tgtttgcgcc cttcatgtcg gtctcgggga 4200
gtcatggggc gtgggaaaca gctgggtggc ttcttagact atggagaaga ggacagttag 4260
gcagacagta gcaagaggag tcacatctga agccagggtg cttgtcctct cagagctgag 4320
tggaccttgt aagtcaacgt gcaacctgct ccccttccca actctggggc agatccttcc 4380
cttcccaaca gtcccatcc atgggtcagg cccttggaga gagggaaaga gagggggaag 4440
tgagggaagg agagagaagg ctccctttag tcttgggtga gctgggcctg acctgagcac 4500
agtgtctggg taacacccag gagccaccgc gcctacctca ggagtccag ggccctgggtg 4560
gggctctagg gagaccctgt tgctgtgtcg cgggtgggtg atgccagtgc cctcggtat 4620
ctggattggc tgcattgtgg ctgggcgag ggtctcttgg ggggtctccag tttcatctc 4680
ctcatctgtg atgggtgccc ggctcaggga aggtgtcatg ggtggaagag gtggtcagt 4740
gaccatagct gtatggagat ggaggaggac ctggggctgt tccagaactc tacactcgcc 4800
cgacacttat ggtcgggacc ctctctgctc acgaggtaga aagacacaag cctccttcc 4860
tgttctgctt tctacctaa cctgggcaa atggcacaag cagtgcagtc ctgaccagat 4920
tctctctga gctcctgct acccccaggg acttcacccc tgagtgccct ccagctgtct 4980
gttccacctg gaacatgaga aggtcacccc tccccctct cggccagtca gtgatccagg 5040
gocctagtgc tcaggctaga tcagcaggtg ggattccaag gaagggcagg gatgggaggc 5100
cctgcacagt gaccccaggc ctacccctgg actccaggga tagcaggtct tcagatgtgg 5160
ggggcacact cgattgcgt gctgcagctc tgcaatgcgg ttccagtcac ccagctgctc 5220
aggctcatcc tggcaagtgc ccatgtagaa gctgttcctt cctgtggaag gcaggggaag 5280
gggaacaaat gagcctggag tcggcaggtc acctcctggc cctggcatct tgccagcctt 5340
tgctgccacc taccocataa acttgaagcc cggcacacca gtctgattca gtgccgcagg 5400
tgcaggagta cggcacacag actatttcta tcttaggggc ttgtcacca ccttctccct 5460
ggagagggca gaagaggtca cagcagaga ctgctactac atcttattca cctgccaaag 5520
cttgggtggc aacacccaga ggaacaaatt aaggaccggg aattaattcc caggggctcc 5580
ctgggtgccc aaggacaaga gcttccaaga agagtctggc cagcctggcc tttccagcag 5640
cccatcaccg cctgagaagg gcatggagga ctccccacag ctaagtgtca caattgtgct 5700
gggaatcccg ggcccttaac tctggctaag agtgccccc aacacagccag cccctagatg 5760
ggcaggtaag gaaggccctg aggtgtcagg aaggaggggc aggtggagct ggatggtagc 5820
aaggaggcca gccttggatt tttaaaaagc tttcctcttt tccctgtgcc acgatccacc 5880
ttccagtcta attttgggg atagtaagtc cctgtagtcc cctcacctgg aggggcccc 5940
ctggacaccc cggcctggga acgacagaca gaactgcgag tgggtggggc gtagccaggc 6000
aagctgagca gggctgagtt gccataatcg ggagaacca ggcgagctag agactgagta 6060
gaggaggtgg ctgcaggtc agcctgggaa gcaggagcag accgcgtgct gtagaacgat 6120
gagttgggcg tgtctggctc ttccacatct agcttctgga agacagagtg aatctgttgc 6180
agtgtacagt cctggcaact gtacagaagc ttccattcc cttccgaagc cctcagatcc 6240
cacggcacat ccatgtattc ccaactgctt tgcaaaggtc cttaaagtgt gtgtctgcaa 6300
gaaatgggccc ttgtcgacag aagccctcac aagggtgtgc tgatgtgtc aagactcttc 6360
tacgcatttt tttcatggag tctattcata atgctttgag gtagggaatg cagagtgttt 6420

```

```

atcgggcccat tttggagatg aagtgcaaag aaataaagtg actagcccca aatcacactg 6480
ctaggaagta tcagagctgg ggctaggccc catgtctcct gactagtcag gctcatccca 6540
cagcctctgc tgccctcag tccaaacttc cagggccctt accatgttcc agaacttccc 6600
ccaaacttctt ggtagcaggg ggcaccctaa acacacaggt ccccccctgct gtaccagggg 6660
ccccctctcc cctcctccca aacctccctt tcaagatgtg gaaacaaagg caagggcctg 6720
cagcctgtca ggcagtccac tgggcagcaa caatgcctct cagctgcatg gggcatgctg 6780
ggaggcacag gatgggctgc agcttcgcca cgttctctcc cttcaccctg cacaggctca 6840
gtgctacgca tggagagaat gctagcctta gtcaggaggg agggatctaa tcctagccct 6900
gcctttttct tcagaagtgc ccttaaccaa gtcactgccc tttttaagac ctctcagctt 6960
tcccactgta acatggactg gctgctcatt cctccctgct cctgactgag tgcccagtgc 7020
aaagatgccc ttgagaggaa gtggaattg ctgacctgac gac 7063

```

<210> 6

<211> 197

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> (1)..(28)

<400> 6

```

Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val Leu Leu
  1              5              10              15

```

```

Leu Cys Ala His Val Val Thr Leu Leu Val Arg Ala Thr Pro Val Ser
          20              25              30

```

```

Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys Asp Pro
      35              40              45

```

```

Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys Pro Ala
      50              55              60

```

```

Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Asn Gly Thr Leu
      65              70              75              80

```

```

Ser Leu Ser Cys Val Ala Cys Ser Arg Phe Pro Asn Phe Ser Ile Leu
          85              90              95

```

```

Tyr Trp Leu Gly Asn Gly Ser Phe Ile Glu His Leu Pro Gly Arg Leu
      100              105              110

```

```

Trp Glu Gly Ser Thr Ser Arg Glu Arg Gly Ser Thr Gly Thr Gln Leu
      115              120              125

```

```

Cys Lys Ala Leu Val Leu Glu Gln Leu Thr Pro Ala Leu His Ser Thr
      130              135              140

```

Asn Phe Ser Cys Val Leu Val Asp Pro Glu Gln Val Val Gln Arg His
 145 150 155 160

Val Val Leu Ala Gln Leu Trp Val Arg Ser Pro Arg Arg Gly Leu Gln
 165 170 175

Glu Gln Glu Glu Leu Cys Phe His Met Trp Gly Gly Lys Gly Gly Leu
 180 185 190

Cys Gln Ser Ser Leu
 195

<210> 7

<211> 1360

<212> DNA

<213> Homo sapiens

<400> 7

```

gcgggccgcgt cgaccacgca gctaaacaca gctaacttga gtcttggagc tcttaaaggg 60
aagcttctgtg aaaggaaggc tcttcaggac ctcttaggag ccaaagaaga ggacgttgtc 120
acagataaag agccaggctc accagctcct gacgcattga tcatgaccat gagacacaac 180
tggacaccag acctcagccc ttgtgggtc ctgctcctgt gtgcccacgt cgtcactctc 240
ctggtcagag ccacacctgt ctgcagacc accacagctg ccaactgcctc agttagaagc 300
acaaaggacc cctgccccctc ccagccccc gtgttcccag cagctaagca gtgtccagca 360
ttggaagtga cctggccaga ggtggaagtg ccaactgaatg gaacgctgag cttatcctgt 420
gtggcctgca gccgttccc caacttcagc atcctctact ggctgggcaa tggttccttc 480
attgagcacc tcccaggccg actgtgggag gggagcacca gccgggaacg tgggagcaca 540
ggctgggctg agggcaacct tgccccccac ccaagaagcc ctgccctcca gccacagcag 600
tccacagcag cagggttaag actcagcaca gggccagcag cagcacaacc ttgaccagag 660
cttgggtcct acctgtctac ctggagtga cagtccctga ctgcctgtag gctgcgtgga 720
tgcgcaaacac acccccctct tctctgcttt gggtcccctc tctcaccaaa ttcaaactcc 780
attcccacct acctagaaaa tcacagcctc cttataatgc ctctcctcc tgccattctc 840
tctccacctc tccattagcc ttccaaacgt cctactcctc aactgctct actgctcaga 900
aaccaccaag actgttgatg ccttagcctt gcactccagg gccctacctg catttcccac 960
atgactttct ggaagcctcc caactattct tgcttttccc agacagctcc cactcccctg 1020
tctctgctca tttagtcccg tcttctcac cgcccagca ggggaacgct caagcctggt 1080
tgaaatgctg cctcttcagt gaagtcaccc tctttcagct ctggccgcat tctgcagact 1140
tcctatcttc gtgctgtatg tttttttttt ccccttcac tctaattggac tgttccaggg 1200
aagggatggg ggcagcagct gcttcggatc cacactgtat ctgtgtcatc cccacatggg 1260
tcctcataaa ggattattca atggaggcat cctgacatct gtccatttag gcttcagtcc 1320
cactcccagg aactttgctt gtcccacgag ggagtatggg 1360

```

<210> 8

<211> 161

<212> PRT

<213> Homo sapiens

<220>

<221> SIGNAL

<222> (1)..(28)

<400> 8

Met Arg His Asn Trp Thr Pro Asp Leu Ser Pro Leu Trp Val Leu Leu
 1 5 10 15

Leu Cys Ala His Val Val Thr Leu Leu Val Arg Ala Thr Pro Val Ser
 20 25 30

Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser Thr Lys Asp Pro
 35 40 45

Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys Gln Cys Pro Ala
 50 55 60

Leu Glu Val Thr Trp Pro Glu Val Glu Val Pro Leu Asn Gly Thr Leu
 65 70 75 80

Ser Leu Ser Cys Val Ala Cys Ser Arg Phe Pro Asn Phe Ser Ile Leu
 85 90 95

Tyr Trp Leu Gly Asn Gly Ser Phe Ile Glu His Leu Pro Gly Arg Leu
 100 105 110

Trp Glu Gly Ser Thr Ser Arg Glu Arg Gly Ser Thr Gly Trp Ala Glu
 115 120 125

Gly Asn Leu Ala Pro His Pro Arg Ser Pro Ala Leu Gln Pro Gln Gln
 130 135 140

Ser Thr Ala Ala Gly Leu Arg Leu Ser Thr Gly Pro Ala Ala Ala Gln
 145 150 155 160

Pro

<210> 9

<211> 7812

<212> DNA

<213> Homo sapiens

<400> 9

gtcgacggta ccccgaggaa agatttaata cgactcacta tagggcggga cagaattgat 60
 ctgtgagaga ctcatctagt tcatacccta ggtgaccctg ggggtggcat ggggtagat 120

```

tagagatccc agtctggtat cctctggaga gtaggagctcc caggagctga aggtttctgg 180
ccactgaact ttggctaaag cagaggtgtc acagctgctc aagattccct ggtaaanaag 240
tgaaagtga atagaggggtc ggggcagtg cttcccagaa ggattgctcg gcatcctgcc 300
cttcccagaa gcagctctgg tgcgaagag agcactgcct cctgtgtga ctgggtgagt 360
ccatattctc tctttgggtc tcaattttgc cttcccta at gaaggggtaa gattggacta 420
ggtaagcatc ttacaacat ttgtggtcat gagagctggg gtggggaagg attgtcactt 480
gaccccccca gctctgtttc taagtgtga aagagctcca ggctatgcta cgggaggaga 540
agccagctac tgaggaaaag ccagctactg agaaaaagcg ggagtgggtt accattctcc 600
tccccacct ttaccagag aagaggacgt tgtcacacat aaagagccag gctcaccagc 660
tcctgacgca tgcacatga ccagagaca caactggaca ccaggtaggc cttggggcta 720
cgcatgggca ggggggtag ggtgaggtct atgaacagaa tggagcaatg ggctaaccgg 780
gagccttcac tccaaggcaa accaccagc gcacctgggt ctgttgcttt aagaacctgg 840
gcagatatcg tagctctggc tccagctcaa agcttctctg tactctgttc aataaagggc 900
taaggggtgg gtgctgaggg gtccctcttc ccgctctgat tccctggcta gaaccagac 960
atctctgggc tggagttaca tcttaaccg ggcagccac tctgtctcca gagccgtga 1020
cctgtaactg tctttcctc agacctcagc ctttgtggg tctgtctct gtgtgccac 1080
gtcgtcactc tctggctcag agccacacct gtctcgcaga ccaccacagc tgccactgcc 1140
tcagttagaa gcacaaagga cccctgccc tccagcccc cagtgttccc agcagctaag 1200
cagtgtccag cattggaagt gacctggcca gaggtggaag tgccactgag taagaagcac 1260
agtgggtggg ggtgggctat gggcacagag gtccccaggg tggggttgac tctgagcgc 1320
cagtccctt ctgcccattg accaccagct gagccagctg ggctgagcac gcaccattct 1380
ccctcccaa cccagtgtca tgggtgcagg cttggcgag ctcccaagat gctccctatc 1440
aaataggaca gagaactcaa gacataagta atggctcacag gacctccag agccttggtt 1500
gcagtggacc ccaaggccag cccctccacc cagagcctgc tggcctctgg ccatctcaga 1560
ggagcagcag ccactccagca ctgctctgt cactgggct cccaagtac cgaggctggg 1620
cactagaaaa ggtcatcctg aggagacagg ttcagaagag gattcatcac gtgaaccaag 1680
gaccattcct cacattcccc gtgtttaggg ctagggcctc tcggagacaa ctgcacttct 1740
gtaacggacg tcccaccta ggtggtgtgc agagcagttc tctaggttcc agatgcatgg 1800
ggactggggg gagctggcag agagggcaca gcagagcagg gtagggggaag ggcctgctct 1860
tctgaagagc taactgctgc ctgtgtccct agatggaacg ctgagcttat cctgtgtggc 1920
ctgcagccgc tccccaaact tcagcactct ctactggctg ggcaatggtt ccttcattga 1980
gcacctccca ggccgactgt gggaggggag caccaggtga gggctgcagc agccaggtgg 2040
gtgggaagga agccttctgc ggccttctca tgaccttcc tcccttccg ctccagccgg 2100
gaacgtggga gcacaggtac gcagctgtgc aaggccttgg tgcaggagca gctgacctct 2160
gccctgcaca gcaccaactt ctctgtgtg ctctggacc ctgaacaggt tgtccagcgt 2220
cacgtcgtcc tggccagct ctgggtgagg agcccaagga gaggcctcca ggaacaggag 2280
gagctctgct tccatattgt gggaggaaa ggtgggctct gccagagcag cctgtgaact 2340
aatgcccagc attcctcaag gtcagccaga caaaaaggaa cttaggtctt gggcagagga 2400
ggtgtagcct ggggcaaagt gatgagatgt cctccttct cttggcctga tecttgtctg 2460
ccttcacttc cctaggtgtg gctgagggca accttgcct ccaccaaga agcctgccc 2520
tccagccaca gcagtcaca gcagcagggt taagactcag cacagggcca gcagcagcac 2580
aaccttgacc agagcttggg tctacctgt ctacctggag tgaacagtcc ctgactgcct 2640
gtaggtgog tggatgogca acacacccc tcttctctg ctttgggtcc cttctctcac 2700
caaattcaaa ctccattccc acctacctag aaaatcacag cctccttata atgcctctc 2760
ctctgcat tctctctcca cctatccatt agccttcta acgtcctact cctcacactg 2820
ctctactgct cagaaaccac caagactgt gatgccttag ccttgactc cagggcccta 2880
cctgcatttc ccacatgact ttctggaagc ctcccaacta ttcttgcttt tccagacag 2940
ctccactcc catgtctctg ctcatctagt cccgtcttcc tcaccgccc agcaggggaa 3000

```

```

cgctcaagcc tggttgaaat gctgcctctt cagtgaagtc atcctctttc agctctggcc 3060
gcattctgca gacttcctat cttcgtgctg tatgtttttt ttttccccct tcaactctaat 3120
ggactgttcc aggggaaggga tgggggcagc agctgcttcg gatccacact gtatctgtgt 3180
catccccaca tgggtcctca taaaggatta ttcaatggag gcatcctgac atctgttcat 3240
ttaggcttca gttccactcc caggaacttt gctgtccca cgagggagta tgggagagat 3300
ggactgccac acagaagctg aagacaacac ctgcttcagg ggaacacagg cgcttgaaaa 3360
agaaaagaga gaacagccca taatgtctcc cgggagcaga ggccactaat ggagagtggg 3420
aagagcctgg aaagatgtgg cctcaggaaa agggatgaga gaaaggagggt ggtatggaag 3480
actcagcagg aacaaggtag gcttcaaaga gcctatatct ctctttttcc cacaccgatc 3540
aagtcaactc agtactcacg ggagaaaaat agactttatt tacaagtaat aacatttaga 3600
aaagatccat ccccggccct taaaaacctt cccatcactc caaatcccac cccagtgcac 3660
gtctggggaa ggtaggggtg gagctgctgc tgaaggctgt cccccaaccc cactcctgag 3720
acacagggcc catccgtcct gggaaagagc atcctctggc aggtgctccc accaggtcag 3780
accagtcctt ggacttcaag agtgagggcc cctgctgggc ccagccacca ggacagcagg 3840
aaccagggcc tactcctctt atgggtccctt ctagatccag aggctaagag gaagactggc 3900
caggcccaag gaccagcca tcaaaaccag cctcaaatct ggttggtgatg gagaagtgc 3960
tttgctttaa gaaaaaagga ggcaaggtag ggagagcgcc cacactgtcc atgctccagg 4020
ccccctgggc cagctccgag aaggcgccag tgaaggacca gggaccaggc caggggtgagg 4080
gcaggcatca ctgtctctag gggtttggt actgttggcc tgggagctga gagaaggcac 4140
tgagagggac agtaggcgga ggaccagtg acggcagcat cggggacaca ggtggggcca 4200
ctcactggta ctggcccttt agtgctttgc ctgaaagaga cacagtcaca tggccagatg 4260
agaacttgcg atactagcct gcacccactg gctgggaaga tctcttctctg ctcccacgcc 4320
cctgtctgga tccccctcct tgtgagcccc agggttatca gttgctggct gtgctgagc 4380
agctctgggt gctctccatg agaatggggc catctgtctt ctctccttgg agaggagcta 4440
ccaggacagg gacacctctt accccacacc ctccagcagc ctggcgtggc cccatcttgg 4500
atgctacttg gtggggcggt ctgggggggtg cccatgtctt catcggttt cctccccc 4560
tcctgccagt gcctctacct tgccttggc tggaggggtg gcaccaatgg cggcagcagt 4620
ggcgcgctg gctgtggtgg tggcaatgcg cggagaacgg cgggttccac tgcgagtgtt 4680
gggggaagcc ttggacagg ccttctttga ggctccccgc cgcagaaggc tgttccctag 4740
cttcttgggt gtgttgagga tgctgaaggc catcgactgg cgcgggtcag cctgcaagga 4800
agggctgtca gaccgggaga cccaatgctg ccttcccagg ccagcgtgct gtgccaagct 4860
gtaccagcaa ggtcccgcca gggcgtcgt tcatccccct tcagccccag cctcaactgt 4920
ttagtagaag ctggagctgc tttctctctg gcctcagtag tgcctgttt gcgcccttca 4980
tgtcggctct cgggagtcac ggggcgtggg aaacagctgg tggccttctt agactatgga 5040
gaagaggaca gttaggcaga cagtagcaag aggagtcaca tctgaagcca ggtgtcttgt 5100
cctctcagag ctgagtggac cttgtaagtc aacgtgcaac ctgctcccc tcccaactct 5160
gggccagatc cttcccttcc caacagttcc catccatggg tcaggccctt ggagagaggg 5220
aaagagaggg ggaagtggg gaaggagaga gaaggctccc tttagtcctt ggtgagctgg 5280
gcctgacctg agcacagtgc tggagtaaca ccaggagcc accgcgccta cctcaggagt 5340
tccagggccc tgggtggggc ctagggagac ccgtttgcgc tgcctgggg tggatgccc 5400
agtgcctcgt gctatctgga ttggctgcat gctggctcgg cgcagggtct cttgggggtc 5460
tccagttttc atctcctcat ctgtgatggt gcccaggctc aggggaaggct gcatgggtgg 5520
aagaggtggt cagtggacca tagctgtatg gagatggagg aggacctggg gctgttccag 5580
aactctacac tcgcccagaca cttatggctg ggacccttcc tgcctacgag gtagaaagac 5640
acaagcctcc tttcctgttc tgctttctac ctaagccctg ggcaaatggc acaagcagtg 5700
cagtcctgac cagattcctc tctgagctcc tgcctacccc cagggacttc acccctgagt 5760
gccctccagc tgtctgttcc acctggaaca tgagaaggct accccttccc ctcttcggcc 5820
agtccagtga ccagggccct agtgctcagg ctagatcagc aggtgggatt ccaaggaagg 5880

```



```

gcagggatgg gaggccctgc acagtgaccc caggcctcac cctggactcc agggatagca 5940
ggtcttcaga tgtggggggc acactcgatt gcgctgctgc agctctgcaa tgcggttcca 6000
gtcatccagc tgctcaggct catcctggca agtgcccatg tagaagctgt tccttcctgt 6060
ggaaggcagg gaagtgggaa caaatgagcc tggagtcggc aggtcacctc ctggccctgg 6120
catcttgcca gcctttgctg ccacctaccc cataaacttg aagcccggca caccagtctg 6180
attcagtgcc gcagggtgcag gagtacggca cacagactat ttctatccta ggggcttgct 6240
caccaccttc tccctggaga gggcagaaga ggtcacacgc agagactgct actacatctt 6300
attcacctgc caaggcttgg tggccaacac ccagaggaac aaattaagga cggggaatta 6360
attcccaggg gctccctggg gcccaaagga caagagcttc caagaagagt ctggccagcc 6420
tggcctttcc agcagcccat caccgcctga gaagggcagc gaggactccc cacagctaag 6480
tgtcacaatt gtgctgggaa tcccggggcc ttaactctgg ctaagagtgc cccaacaca 6540
gccagccctc agatgggcag gtaaggaagg ccctgaggct gcaggaagga ggggcagggt 6600
gagctggatg gtagcaagga ggccagcctt ggatttttaa aaagctttcc tcttttccct 6660
gtgccacgat ccaccttcca gtctaatttt ggggtatagt aagtccctgt agtcccctca 6720
cctggagggg ccccaactga cccccggcc tgggaacgac gagcagaact gcgagtgggt 6780
gggcggtagc caggcaagct gagcagggct gagttgccat aatcgggaga acccaggcga 6840
gctagagact gagtagagga ggtggctcgc aggtagcctt gggaagcagg agcagaccgc 6900
gtgctgtaga acgatgagtt ggcgctgtct ggctcttcca catctagctt ctggaagaca 6960
gagtgaatct gttgcagtgt acagtccttg gcactgtaca gaagcttccc attcccttcc 7020
gaagccctca gatccacagg cacatccatg tattcccaac tgctttgcaa aggtccctaa 7080
agtgtgtgtc tgcaagaaat gggccttgct gacagaagcc ctcaacaagg ggtgctgatg 7140
ttgtcaagac tcttctaagc atttttttca tggagtctat tcataatgct ttgaggtagg 7200
gaatgcagag tgtttatcgg cccattttgg agatgaagtg caaagaaata aagtgactag 7260
ccccaaatca cactgctagg aagtatcaga gctggggcta ggccccatgt ctctgacta 7320
gtcaggctca tcccacagcc tctgctgtcc ctcagtccaa acttccaggg cccttaccat 7380
gttccagaac ttcccccaac ttcttggtag cagggggcac cctaaacaca cagggtcccc 7440
ctgctgtacc aggggcccc tctccctccc tcccaaacct ccccttcaag atgtggaaac 7500
aaaggcaagg gcctgcagcc tgtcaggcag tccactgggc agcaacaatg cctctcagct 7560
gcatggggca tgctgggagg cacaggatgg gctgcagctt cgccacgttc tctcccttca 7620
ccctgcacag gctcagtgtc acgcatggag agaatgctag ccttagtcag gaggcaggga 7680
tctaactcta gccctgcctt tttcttcaga agtgccctta accaagtcac tgcccttttt 7740
aagacctctc agcttttcca ctgtaacatg gactggctgc tcatccctcc ctgctcctga 7800
ctgagtgccc ag 7812

```

<210> 10

<211> 40

<212> PRT

<213> Homo sapiens

<400> 10

```

Thr Pro Val Ser Gln Thr Thr Thr Ala Ala Thr Ala Ser Val Arg Ser
1 5 10 15

```

```

Thr Lys Asp Pro Cys Pro Ser Gln Pro Pro Val Phe Pro Ala Ala Lys
20 25 30

```

```

Gln Cys Pro Ala Leu Glu Val Thr
35 40

```

Claims:

1. An IL-18 binding protein (IL-18BP) including the amino acid sequence of SEQ ID
NO:10, muteins, fused proteins, functional derivatives, active fractions, circularly
permuted derivatives and mixtures thereof.
2. IL-18BP according to claim 1, capable of at least one of the following :
 - (i) binding to IL-18,
 - (ii) modulating the activity of IL-18,
 - (iii) blocking the activity of IL-18.
3. IL-18BP selected from the group consisting of :
 - (a) polypeptides comprising any one of the amino acid sequences of SEQ ID
NO:2, 4, 6, or 8;
 - (b) polypeptides as defined in (a) without a leader sequence;
 - (c) muteins, fused proteins, functional derivatives, active fractions, circularly
permuted derivatives and mixtures thereof of the polypeptides defined in (a)
or (b); and
 - (d) viral homologues of the polypeptides defined in (a) or (b).
4. IL-18BP according to claim 3, having at least one of the following biological
properties :
 - (i) binding to IL-18,
 - (ii) modulating the activity of IL-18;
 - (iii) blocking the activity of IL-18.
5. IL-18BP according to any one of claims 1-4 being a non-viral protein.
6. IL-18BP according to claim 5, being a human protein.

7. IL-18BP according to any one of claims 1-6, having a molecular weight of about 40 kD.
8. IL-18BP according to any one of claims 1 to 7, being a fused protein.
- 5 9. A protein comprising an IL-18BP according to any one of claims 1-8.
10. IL-18BP according to any one of claims 1 to 9 in soluble form.
11. IL-18BP according to any one of claims 1 to 10, being non-glycosylated IL-18BP.
- 10 12. A DNA capable of hybridizing under stringent conditions, or which would be capable of hybridizing under stringent conditions but for the degeneracy of the genetic code to at least one of the DNA sequences shown in SEQ ID NO: 1, 3, 5 or 7, said DNA being capable of encoding an IL-18BP according to any one of claims 1 to 11.
- 15 13. A DNA encoding an IL-18BP according to any one of claims 1 to 11, including the amino acid sequence of SEQ ID NO:10.
14. A DNA encoding an IL-18BP according to any one of claims 1 to 11, including the amino acid sequence of SEQ ID NO:10 provided with a stop codon at its 3' end.
- 20 15. A DNA which hybridizes to the DNA of claim 13 under stringent conditions or which would be capable of hybridizing under stringent conditions but for the degeneracy of the genetic code, capable of encoding an IL-18BP according to any one of claims 1-11.
- 25 16. A DNA according to any one of claims 12 to 15 operatively linked to other DNA sequences facilitating expression, such as promoters, enhancers and the like.
- 30 17. A DNA according to any one of claims 12 to 16, being a genomic DNA.

18. A DNA according to any one of claims 12 to 17, being a cDNA.
19. A cDNA according to claim 18, comprising a cDNA sequence selected from the group of DNA sequences of SEQ ID NO:1, 3, 5 and 7.
- 5 20. A cDNA according to claims 18 or 19, being adapted for expression in a bacterial host.
21. A replicable expression vehicle comprising a DNA according to any one of claims 12 to 20.
- 10 22. A transformed host cell comprising an expression vehicle according to claim 21.
23. A transformed host cell according to claim 22, being a eukaryotic cell.
- 15 24. A transformed host cell according to claim 22, being a prokaryotic cell.
25. A process for the production of IL-18BP according to any one of claims 1 to 11, comprising culturing a host cell according to any one of claims 21 to 23 under conditions suitable for expression of said IL-18BP, and isolating said IL-18BP.
- 20 26. An antibody to IL-18BP according to any one of claims 1 to 11.
27. An antibody according to claim 26, being a polyclonal antibody.
- 25 28. An antibody according to claim 26, being a monoclonal antibody.
29. An antibody according to claim 26, being an anti-idiotypic antibody.
- 30 30. An antibody according to claim 26, being a chimeric antibody.

31. An antibody according to claim 26, being a humanized antibody.
32. A process for the isolation of IL-18BP according to claim 3, comprising :
- 5 (a) passing a human fluid through a chromatographic column to which IL-18 is coupled,
- (b) eluting the protein capable of binding to IL-18, and
- (c) purifying said protein.
33. A pharmaceutical composition comprising IL-18BP according to any one of claims
- 10 1 to 11.
34. A pharmaceutical composition comprising a virus encoded homologue of IL-18BP according to any one of claims 1 to 11.
- 15 35. A pharmaceutical composition comprising a DNA encoding IL-18BP according to any one of claims 1-11.
36. Use of IL-18BP according to any one of claims 1 to 11 in the preparation of a pharmaceutical composition for the treatment of conditions requiring administration
- 20 of IL-18BP.
37. Use of a virus encoded homologue of IL-18BP according to any one of claims 1 to 11 in the preparation of a pharmaceutical composition for the treatment of conditions requiring administration of IL-18BP.
- 25 38. Use of IL-18BP according to any one of claims 1 to 11 for the purification of IL-18.
39. Use of the antibodies according to any one of claims 26 to 31 in an assay for the detection of IL-18BP.
- 30

40. Use of a DNA encoding IL-18BP according to any one of claims 1 to 11 or encoding a virus encoded homologue of said IL-18BP for gene therapy.

41. Use of a DNA according to any one of claims 12 to 20 for making an IL-18BP according to any one of claims 1-11.

5

10

15

20

25




FIG. 1

2/25




FIG. 2




FIG. 3a

4/25




Fig. 3 B-D

5/25




Fig. 3E

6/25

IL-18Bpa; DNA sequence:

Length: 1348 December 14, 1997 15:41 Type: N Check: 2207 ..

1 GAGAAGAGGA CGTTGTCACA GATAAAGAGC CAGGCTCACC AGCTCCTGAC
51 GCATGCATCA TGACCATGAG ACACAACTGG ACACCAGACC TCAGCCCTTT
101 GTGGGTCCTG CTCCTGTGTG CCCACGTCGT CACTCTCCTG GTCAGAGCCA
151 CACCTGTCTC GCAGACCACC ACAGCTGCCA CTGCCTCAGT TAGAAGCACA
201 AAGGACCCCT GCCCCTCCCA GCCCCCAGTG TTCCCAGCAG CTAAGCAGTG
251 TCCAGCATTG GAAGTGACCT GGCCAGAGGT GGAAGTGCCA CTGAATGGAA
301 CGCTGAGCTT ATCCTGTGTG GCCTGCAGCC GCTTCCCCAA CTTCAGCATC
351 CTCTACTGGC TGGGCAATGG TTCCTTCATT GAGCACCTCC CAGGCCGACT
401 GTGGGAGGGG AGCACCAGCC GGGAACGTGG GAGCACAGGT ACGCAGCTGT
451 GCAAGGCCTT GGTGCTGGAG CAGCTGACCC CTGCCCTGCA CAGCACCAAC
501 TTCTCCTGTG TGCTCGTGGA CCCTGAACAG GTTGTCCAGC GTCACGTCGT
551 CCTGGCCCAG CTCTGGGCTG GGCTGAGGGC AACCTTGCCC CCCACCCAAG
601 AAGCCCTGCC CTCCAGCCAC AGCAGTCCAC AGCAGCAGGG TTAAGACTCA
651 GCACAGGGCC AGCAGCAGCA CAACCTTGAC CAGAGCTTGG GTCCTACCTG
701 TCTACCTGGA GTGAACAGTC CCTGACTGCC TGTAGGCTGC GTGGATGCGC
751 AACACACCCC CTCCTTCTCT GCTTTGGGTC CTTTCTCTCA CCAAATTCAA
801 ACTCCATTCC CACCTACCTA GAAAATCACA GCCTCCTTAT AATGCCTCCT
851 CCTCCTGCCA TTCTCTCTCC ACCTATCCAT TAGCCTTCCT AACGTCCTAC
901 TCCTCACACT GCTCTACTGC TCAGAAACCA CCAAGACTGT TGATGCCTTA
951 GCCTTGCACT CCAGGGCCCT ACCTGCATTT CCCACATGAC TTTCTGGAAG
1001 CCTCCCAACT ATTCTTGCTT TTCCCAGACA GCTCCCACTC CCATGTCTCT
1051 GCTCATTTAG TCCCGTCTTC CTCACCGCCC CAGCAGGGGA ACGCTCAAGC
1101 CTGGTTGAAA TGCTGCCTCT TCAGTGAAGT CATCCTCTTT CAGCTCTGGC
1151 CGCATTCTGC AGACTTCCTA TCTTCGTGCT GTATGTTTTT TTTTCCCCC
1201 TTCACTCTAA TGGACTGTTT CAGGGAAGGG ATGGGGGCAC CAGCTGCTTC

Fig. 4

7/25

1251 GGATCCACAC TGTATCTGTG TCATCCCCAC ATGGGTCCTC ATAAAGGATT

1301 ATTCAATGGA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

(SEQ ID NO:1)

IL-18Bpa; Protein sequence:

Length: 192 June 5, 1998 13:39 Type: P Check: 3073 ..

1 MRHNWTPDLS PLWVLLCAH VVTLLVRATP VSQTTTAATA SVRSTKDPCP

51 SQPPVFPAAK QCPALEVTWP EVEVPLNGTL SLSCVACSRF PNFSILYWLG

101 NGSFIEHLPGLWEGSTSRE RGSTGTQLCK ALVLEQLTPA LHSTNFCVCL

151 VDPEQVVQRH VVLAQLWAGL RATLPPTQEA LPSSHSSPQQ QG

(SEQ ID NO:2)

Fig. 4A

8/25

IL-18BPb; DNA sequence

Length: 1038 June 19, 1998 14:10 Type: N Check: 8005 ..

1 GAGAAGAGGA CGTTGTCACA GATAAAGAGC CAGGCTCACC AGCTCCTGAC
51 GCATGCATCA TGACCATGAG ACACAACTGG ACACCAGACC TCAGCCCTTT
101 GTGGGTCCTG CTCCTGTGTG CCCACGTCGT CACTCTCCTG GTCAGAGCCA
151 CACCTGTCTC GCAGACCACC ACAGCTGCCA CTGCCTCAGT TAGAAGCACA
201 AAGGACCCCT GCCCCTCCCA GCCCCCAGTG TTCCCAGCAG CTAAGCAGTG
251 TCCAGCATTG GAAGTGACCT GGCCAGAGGT GGAAGTGCCA CTGAGCTGGG
301 CTGAGGGCAA CCTTGCCCCC CACCCAAGAA GCCCTGCCCT CCAGCCACAG
351 CAGTCCACAG CAGCAGGGTT AAGACTCAGC ACAGGGCCAG CAGCAGCACA
401 ACCTTGACCA GAGCTTGGGT CCTACCTGTC TACCTGGAGT GAACAGTCCC
451 TGA CTGCCTG TAGGCTGCGT GGATGCGCAA CACACCCCCT CCTTCTCTGC
501 TTTGGGTCCC TTCTCTCACC AAATTCAAAC TCCATTCCCA CCTACCTAGA
551 AAATCACAGC CTCCTTATAA TGCCTCCTCC TCCTGCCATT CTCTCTCCAC
601 CTATCCATTA GCCTTCCTAA CGTCCTACTC CTCACACTGC TCTACTGCTC
651 AGAAACCACC AAGACTGTTG ATGCCTTAGC CTTGCACTCC AGGGCCCTAC
701 CTGCATTTC CACATGACTT TCTGGAAGCC TCCCAACTAT TCTTGCTTTT
751 CCCAGACAGC TCCCCTCCC ATGTCTCTGC TCATTAGTC CCGTCTTCCT
801 CACCGCCCCA GCAGGGGAAC GCTCAAGCCT GGTTGAAATG CTGCCTCTTC
851 AGTGAAGTCA TCCTCTTTCA GCTCTGGCCG CATTCTGCAG ACTTCCTATC
901 TTCGTGCTGT ATGTTTTTTT TTTCCCCCTT CACTCTAATG GACTGTTCCA
951 GGGAAGGGAT GGGGGCACCA GCTGCTTCGG ATCCACACTG TATCTGTGTC
1001 ATCCCCACAT GGGTCCTCAT AAAGGATTAT TCAATGGA

(SEQ ID NO:3)

Fig. 5

9/25

huIL-18BPb
Clone-m7
peptide

1 MRHNWTPD LSPLWVLLC AHVVTLLVRA TPVSQTTTAA TASVRSTKDP
49 CPSQPPVFPA AKQCPALEVT WPEVEVPLSW AEGNLAPHPR SPALQPQQST
99 AAGLRLSTGP AAAQP*

(SEQ ID NO:4)

Fig. 5A

10/25

hulL18BPc.seq Length: 7063 July 16, 1998 19:47 Type: N Check: 9314 ..

1 GAATTCGCGG CCGCGTCGAC GCCAGAGGGG CTAGGATGAG AGACAGAGGG
51 TGTGATGGTG GGTGCTGGGA AATGTACCCG ACCTTGGGGC TGGTGGCTGG
101 GGGAGTGGGT AGCCTGGGAA AGGCCAGGAT GTGGACGGAC TGGTATGGCA
151 TTGAGCCTGA AGTGGTCCAA CTTGGGGTTC CCCAGTGCCT AGGAAAGTTG
201 TCCCCTTGAA TGTCAGTGTG AAGGTGAAGG AGGAAGCAGA TGCCTGTTCA
251 TATGGAAACA AAGACCTGGC TGTGAAGAGG GGAGGCGGAC ACCAAAGTCC
301 TGACACTTGG GCGGGACAGA ATTGATCTGT GAGAGACTCA TCTAGTTCAT
351 ACCCTAGGTG ACCCTGGGGG TGGCATGGGG GTAGATTAGA GATCCCAGTC
401 TGGTATCCTC TGGAGAGTAG GAGTCCCAGG AGCTGAAGGT TTCTGGCCAC
451 TGAAC TTTGG CTAAAGCAGA GGTGTCACAG CTGCTCAAGA TTCCCTGGTT
501 AAAAAGTGAA AGTGAAATAG AGGGTCGGGG CAGTGCTTTC CCAGAAGGAT
551 TGCTCGGCAT CCTGCCCTTC CCAGAAGCAG CTCTGGTGCT GAAGAGAGCA
601 CTGCCTCCCT GTGTGACTGG GTGAGTCCAT ATTCTCTCTT TGGGTCTCAA
651 TTTTGCCTTC CCTAATGAAG GGGTAAGATT GGACTAGGTA AGCATCTTAC
701 AACCATTTGT GGTCATGAGA GCTGGGGTGG GGAAGGATTG TCACTTGACC
751 CCCCCAGCTC TGTTTCTAAG TGCTGAAAGA GCTCCAGGCT ATGCTACGGG
801 AGGAGAAGCC AGCTACTGAG GAAAAGCCAG CTA CTGAGAA AAAGCGGGAG
851 TGGTTTACCA TTCTCCTCCC CCACCTTTCA CCAGAGAAGA GGACGTTGTC
901 ACACATAAAG AGCCAGGCTC ACCAGCTCCT GACGCATGCA TCATGACCAT
951 GAGACACAAC TGGACACCAG ACCTCAGCCC TTTGTGGGTC CTGCTCCTGT
1001 GTGCCCACGT CGTCACTCTC CTGGTCAGAG CCACACCTGT CTCGCAGACC
1051 ACCACAGCTG CCACTGCCTC AGTTAGAAGC ACAAAGGACC CCTGCCCCTC
1101 CCAGCCCCCA GTGTTCCCAG CAGCTAAGCA GTGTCCAGCA TTGGAAGTGA
1151 CCTGGCCAGA GGTGGAAGTG CCACTGAATG GAACGCTGAG CTTATCCTGT
1201 GTGGCCTGCA GCCGCTTCCC CAACTTCAGC ATCCTCTACT GGCTGGGCAA

Fig. 6

11/25

1251 TGGTTCCTTC ATTGAGCACC TCCCAGGCCG ACTGTGGGAG GGGAGCACCA
1301 GCCGGGAACG TGGGAGCACA GGTACGCAGC TGTGCAAGGC CTTGGTGCTG
1351 GAGCAGCTGA CCCCTGCCCT GCACAGCACC AACTTCTCCT GTGTGCTCGT
1401 GGACCCTGAA CAGGTTGTCC AGCGTCACGT CGTCCTGGCC CAGCTCTGGG
1451 TGAGGAGCCC AAGGAGAGGC CTCCAGGAAC AGGAGGAGCT CTGCTTCCAT
1501 ATGTGGGGAG GAAAGGGTGG GCTCTGCCAG AGCAGCCTGT GAACTAATGC
1551 CCAGCATTC CCAAGGTCAG CCAGACAAAA AGGAACTTAG GTCTTGGGCA
1601 GAGGAGGTGT AGCCTGGGGC AAAGTGATGA GATGTCCCTC CTTTCCTTGG
1651 CCTGATCCTT GTCTGCCTTC ACTTCCCTAG GCTGGGCTGA GGGCAACCTT
1701 GCCCCCACC CAAGAAGCCC TGCCCTCCAG CCACAGCAGT CCACAGCAGC
1751 AGGGTTAAGA CTCAGCACAG GGCCAGCAGC AGCACAACCT TGACCAGAGC
1801 TTGGGTCCTA CCTGTCTACC TGGAGTGAAC AGTCCCTGAC TGCCTGTAGG
1851 CTGCGTGGAT GCGCAACACA CCCCTCCTT CTCTGCTTTG GGTCCCTTCT
1901 CTCACCAAAT TCAAACCTCA TTCCCACCTA CCTAGAAAAT CACAGCCTCC
1951 TTATAATGCC TCCTCCTCCT GCCATTCTCT CTCCACCTAT CCATTAGCCT
2001 TCCTAACGTC CTA CTCTCCTCA CACTGCTCTA CTGCTCAGAA ACCACCAAGA
2051 CTGTTGATGC CTTAGCCTTG CACTCCAGGG CCCTACCTGC ATTTCCCACA
2101 TGACTTTCTG GAAGCCTCCC AACTATTCTT GCTTTTCCCA GACAGCTCCC
2151 ACTCCCATGT CTCTGCTCAT TTAGTCCCGT CTTCTCACC GCCCCAGCAG
2201 GGGAACGCTC AAGCCTGGTT GAAATGCTGC CTCTTCAGTG AAGTCATCCT
2251 CTTTCAGCTC TGGCCGCATT CTGCAGACTT CCTATCTTCG TGCTGTATGT
2301 TTTTTTTTTT CCCCTTCACT CTAATGGACT GTTCCAGGGA AGGGATGGGG
2351 GCAGCAGCTG CTTCCGATCC AACTGTATC TGTGTCATCC CCACATGGGT
2401 CCTCATAAAG GATTATTCAA TGGAGGCATC CTGACATCTG TTCATTTAGG
2451 CTTCAGTTCC ACTCCCAGGA ACTTTGCCTG TCCCACGAGG GAGTATGGGA
2501 GAGATGGACT GCCACACAGA AGCTGAAGAC AACACCTGCT TCAGGGGAAC

Fig. 6A

12/25

2551 ACAGGCGCTT GAAAAAGAAA AGAGAGAACA GCCCATAATG CTCCCCGGGA
2601 GCAGAGGCCA CTAATGGAGA GTGGGAAGAG CCTGGAAAGA TGTGGCCTCA
2651 GGAAAAGGGA TGAGAGAAAG GAGGTGGTAT GGAAGACTCA GCAGGAACAA
2701 GGTAGGCTTC AAAGAGCCTA TATTCCTCTT TTTCCACAC CGATCAAGTC
2751 AACTCAGTAC TCACGGGAGA AAAATAGACT TTATTTACAA GTAATAACAT
2801 TTAGAAAAGA TCCATCCCCG GCCCTTAAAA ACCTTCCCAT CACTCCAAAT
2851 CCCACCCCAG TGCAAGTCTG GGGAAGGTAG GGTGTGAGCT GCTGCTGAAG
2901 GCTGTCCCCC AACCCCACTC CTGAGACACA GGGCCCATCC GTCCTGGGAA
2951 AGAGCATCCT CTGGCAGGTG CTCCCACCAG GTCAGACCCA GTCCTGGACT
3001 TCAAGAGTGA GGGCCCCTGC TGGGCCCAGC CACCAGGACA GCAGGAACCA
3051 GGGCCTACTC CTCTTATGGT CCCTTCTAGA TCCAGAGGCT AAGAGGAAGA
3101 CTGGCCAGGC CCAAGGACCC AGCCATCAAA ACCAGCCTCA AATCTGGTTG
3151 TGATGGAGAA GTGACTTTGC TTAAAGAAAA AAGGAGGCAA GGTAGGGAGA
3201 GCGCCACAC TGTCCATGCT CCAGGCCCCC TGGGCCAGCT CCGAGAAGGC
3251 GCCAGTGAAG GACCAGGGAC CAGGCCAGGG TGCGGGCAGG CATCACTGTC
3301 TCTAGGGGTT TGGCTACTGT TGGCCTGGGA GCTGAGAGAA GGCCTGAGA
3351 GGGACAGTAG GCGGAGGACC AGGTGACGGC AGCATCGGGG ACACAGGTGG
3401 GGCCACTCAC TGGTACTGGC CCTTTAGTGC TTTGCCTGAA AGAGACACAG
3451 TCACATGGCC AGATGAGAAC TTGCGATACT AGCCTGCACC CACTGGCTGG
3501 GAAGATCTCT TCCTGCTCCC ACGCCCCTGT CTGGATCCCC TCCCTTGTTGA
3551 GCCCCAGGGT TATCAGTTGC TGGCTGTGCC TGAGCAGCTC TGGGTGCTCT
3601 CCATGAGAAT GGGGCCATCT GTCTTCTCTC CTTGGAGAGG AGCTACCAGG
3651 ACAGGGACAC CTCTTACCCC ACACCCTCCA GCAGCCTGGC GTGGCCCCAT
3701 CTTGGATGCT ACTTGGTGGG GCGGTCTGGG GGGTGCCCAT GCTCTCATCG
3751 GGTTTCCCTC CCCCATCCTG CCAGTGCCTC TACCTTGCCC TTGGCTCGAG
3801 GGGTGGCACC AATGGCGGCA GCAGTGGCGG CGCTGGCTGT GGTGGTGGCA

Fig. 6B

13/25

3851 ATGCGCGGAG AACGGCGGGT TCCACTGCGA GTGTTGGGGG AAGCCTTGGA
3901 CAGGGCCTTC TTTGAGGCTC CCCGCCGCAG AAGGCTGTTC CCTAGCTTCT
3951 TGGGTGTGTT GAGGATGCTG AAGGCCATCG ACTGGCGCCG GTCAGCCTGC
4001 AAGGAAGGGC TGTCAGACCG GGAGACCCAA TGCTGCCTTC CCAGGCCAGC
4051 GTGCTGTGCC ACGCTGTACC AGCAAGGTCC CGCCAGGGCG TCGCTTCATC
4101 CCCCTTCAGC CCCAGCCTCA CCTGTTTAGT AGAAGCTGGA GCTGCTTTCT
4151 TCTGGGCCTC AGTAGTGCTC TGTTTGCGCC CTTTCATGTCG GTCTCGGGGA
4201 GTCATGGGGC GTGGGAAACA GCTGGTGGCC TTCTTAGACT ATGGAGAAGA
4251 GGACAGTTAG GCAGACAGTA GCAAGAGGAG TCACATCTGA AGCCAGGTGT
4301 CTTGTCCTCT CAGAGCTGAG TGGACCTTGT AAGTCAACGT GCAACCTGCT
4351 CCCCTTCCCA ACTCTGGGCC AGATCCTTCC CTTCCCAACA GTTCCCATCC
4401 ATGGGTCAGG CCCTTGGAGA GAGGGAAAGA GAGGGGGAAG TGAGGGAAGG
4451 AGAGAGAAGG CTCCCTTTAG TCCTTGGTGA GCTGGGCCTG ACCTGAGCAC
4501 AGTGCTGGAG TAACACCCAG GAGCCACCGC GCCTACCTCA GGAGTTCCAG
4551 GGCCCTGGTG GGGCTCTAGG GAGACCCGTT TGCCTGCTG CCGGGTGGTG
4601 ATGCCAGTGC CCTCGGCTAT CTGGATTGGC TGCATGCTGG CTCGGCGCAG
4651 GGTCTCTTGG GGGTCTCCAG TTTTCATCTC CTCATCTGTG ATGGTGCCCA
4701 GGCTCAGGGA AGGCTGCATG GGTGGAAGAG GTGGTCAGTG GACCATAGCT
4751 GTATGGAGAT GGAGGAGGAC CTGGGGCTGT TCCAGAACTC TACACTCGCC
4801 CGACACTTAT GGTCTGGGACC CTTCTGCCT ACGAGGTAGA AAGACACAAG
4851 CCTCCTTTCC TGTTCTGCTT TCTACCTAAG CCCTGGGCAA ATGGCACAAG
4901 CAGTGCAGTC CTGACCAGAT TCCTCTCTGA GCTCCTGCCT ACCCCCAGGG
4951 ACTTCACCCC TGAGTGCCCT CCAGCTGTCT GTTCCACCTG GAACATGAGA
5001 AGGTCACCCC TTCCCCTCTT CGGCCAGTCA GTGATCCAGG GCCCTAGTGC
5051 TCAGGCTAGA TCAGCAGGTG GGATTCCAAG GAAGGGCAGG GATGGGAGGC
5101 CCTGCACAGT GACCCCAGGC CTCACCCTGG ACTCCAGGGA TAGCAGGTCT

Fig. 6C

14/25

5151 TCAGATGTGG GGGGCACACT CGATTGCGCT GCTGCAGCTC TGCAATGCGG
5201 TTCCAGTCAT CCAGCTGCTC AGGCTCATCC TGGCAAGTGC CCATGTAGAA
5251 GCTGTTCTT CCTGTGGAAG GCAGGGAAGT GGGAACAAAT GAGCCTGGAG
5301 TCGGCAGGTC ACCTCCTGGC CCTGGCATCT TGCCAGCCTT TGCTGCCACC
5351 TACCCCATAA ACTTGAAGCC CGGCACACCA GTCTGATTCA GTGCCGCAGG
5401 TGCAGGAGTA CGGCACACAG ACTATTTCTA TCCTAGGGGC TTGCTCACCA
5451 CCTTCTCCCT GGAGAGGGCA GAAGAGGTCA CACGCAGAGA CTGCTACTAC
5501 ATCTTATTCA CTGCCAAGG CTTGGTGGCC AACACCCAGA GGAACAAATT
5551 AAGGACCGGG AATTAATTCC CAGGGGCTCC CTGGTGCCCA AAGGACAAGA
5601 GCTTCCAAGA AGAGTCTGGC CAGCCTGGCC TTTCCAGCAG CCCATCACCG
5651 CCTGAGAAGG GCATGGAGGA CTCCCCACAG CTAAGTGTCA CAATTGTGCT
5701 GGGAATCCCG GGCCCTTAAC TCTGGCTAAG AGTGCCCCCA ACACAGCCAG
5751 CCCCTAGATG GGCAGGTAAG GAAGGCCCTG AGGCTGCAGG AAGGAGGGGC
5801 AGGTGGAGCT GGATGGTAGC AAGGAGGCCA GCCTTGGATT TTTAAAAAGC
5851 TTTCTCTTT TCCCTGTGCC ACGATCCACC TTCCAGTCTA ATTTTGGGT
5901 ATAGTAAGTC CCTGTAGTCC CCTCACCTGG AGGGGCCCCA CTGGACACCC
5951 CGGCCTGGGA ACGACGAGCA GAACTGCGAG TGGTGGGGCG GTAGCCAGGC
6001 AAGCTGAGCA GGGCTGAGTT GCCATAATCG GGAGAACCCA GGCGAGCTAG
6051 AGACTGAGTA GAGGAGGTGG CTCGCAGGCT AGCCTGGGAA GCAGGAGCAG
6101 ACCGCGTGCT GTAGAACGAT GAGTTGGCGC TGTCTGGCTC TTCCACATCT
6151 AGCTTCTGGA AGACAGAGTG AATCTGTTGC AGTGACAGT CCCTGGCACT
6201 GTACAGAAGC TTCCATTCC CTTCCGAAGC CTCAGATCC CACGGCACAT
6251 CCATGTATTC CCAACTGCTT TGCAAAGGTC CTAAAGTGT GTGTCTGCAA
6301 GAAATGGGCC TTGTCGACAG AAGCCCTCAC AAGGTGGTGC TGATGTTGTC
6351 AAGACTCTTC TACGCATTTT TTTCATGGAG TCTATTCATA ATGCTTTGAG
6401 GTAGGGAATG CAGAGTGTTT ATCGGCCCAT TTTGGAGATG AAGTGCAAAG

Fig. 6D

15/25

6451 AAATAAAGTG ACTAGCCCCA AATCACACTG CTAGGAAGTA TCAGAGCTGG
6501 GGCTAGGCCC CATGTCTCCT GACTAGTCAG GCTCATCCCA CAGCCTCTGC
6551 TGTCCCTCAG TCCAAACTTC CAGGGCCCTT ACCATGTTCC AGAACTTCCC
6601 CCAACTTCTT GGTAGCAGGG GGCACCCTAA ACACACAGGT CCCCCCTGCT
6651 GTACCAGGGG CCCCCTCTCC CCTCCTCCCA AACCTCCCCT TCAAGATGTG
6701 GAAACAAAGG CAAGGGCCTG CAGCCTGTCA GGCAGTCCAC TGGGCAGCAA
6751 CAATGCCTCT CAGCTGCATG GGGCATGCTG GGAGGCACAG GATGGGCTGC
6801 AGCTTCGCCA CGTTCTCTCC CTTACCCTG CACAGGCTCA GTGCTACGCA
6851 TGGAGAGAAT GCTAGCCTTA GTCAGGAGGC AGGGATCTAA TCCTAGCCCT
6901 GCCTTTTTTCT TCAGAAGTGC CCTTAACCAA GTCAGTCCC TTTTAAGAC
6951 CTCTCAGCTT TCCCAGTGTG ACATGGACTG GCTGCTCATC CCTCCCTGCT
7001 CCTGACTGAG TGCCCAGTGC AAAGATGCCC TTGAGAGGAA GTGGGAATTG
7051 CTGACCTGTC GAC

(SEQ ID NO:5)

IL-18BPc; Protein

Length: 197 June 5, 1998 13:41 Type: P Check: 3353 ..

1 MRHNWTPDLS PLWVLLLCAH VVTLLVRATP VSQTTTAATA SVRSTKDPCP
51 SQPPVFPAAK QCPALEVTWP EVEVPLNGTL SLSCVACSRF PNFSILYWL
101 NGSFIEHLP RLWEGSTSRE RGSTGTQLCK ALVLEQLTPA LHSTNFSCL
151 VDPEQVVQRH VVLAQLWVRS PRRGLQEQUEE LCFHMGWGKG GLCQSSL

(SEQ ID NO:6)

Fig. 6E

16/25

IL-18BPd; DNA

Length: 1360 June 19, 1998 14:55 Type: N Check: 8757 ..

```
1  GCGGCCGCGT CGACCACGCA GCTAAACACA GCTAACTTGA GTCTTGGAGC
51 TCCTAAAGGG AAGCTTCTGG AAAGGAAGGC TCTTCAGGAC CTCTTAGGAG
101 CCAAAGAAGA GGACGTTGTC ACAGATAAAG AGCCAGGCTC ACCAGCTCCT
151 GACGCATGCA TCATGACCAT GAGACACAAC TGGACACCAG ACCTCAGCCC
201 TTTGTGGGTC CTGCTCCTGT GTGCCACGT CGTCACTCTC CTGGTCAGAG
251 CCACACCTGT CTCGACAGAC ACCACAGCTG CCACTGCCTC AGTTAGAAGC
301 ACAAAGGACC CCTGCCCCTC CCAGCCCCCA GTGTTCCCAG CAGCTAAGCA
351 GTGTCCAGCA TTGGAAGTGA CCTGGCCAGA GGTGGAAGTG CCACTGAATG
401 GAACGCTGAG CTTATCCTGT GTGGCCTGCA GCCGCTTCCC CAACTTCAGC
451 ATCCTCTACT GGCTGGGCAA TGGTTCCTTC ATTGAGCACC TCCCAGGCCG
501 ACTGTGGGAG GGGAGCACCA GCCGGGAACG TGGGAGCACA GGCTGGGCTG
551 AGGGCAACCT TGCCCCCACC CCAAGAAGCC cTGCCCTCCA GCCACAGCAG
601 TCCACAGCAG CAGGGTTAAG ACTCAGCACA GGGCCAGCAG CAGCACAACC
651 TTGACCAGAG CTTGGGTCCT ACCTGTCTAC CTGGAGTGAA CAGTCCCTGA
701 CTGCCTGTAG GCTGCGTGGA TGCGCAACAC ACCCCCTCCT TCTCTGCTTT
751 GGGTCCCTTC TCTACCAAAA TTCAAaCTCC ATTCCCACCT ACCTAGAAAA
801 TCACAGCCTC CTTATaATGC CTCCTCCTCC TGCCATTCTC TCTCCACCTA
851 TCCATTAGCC TTCCTAACGT CCTACTCCTC AACTGCTCT ACTGCTCAGA
901 AACCACCAAG ACTGTTGATG CCTTAGCCTT GCACTCCAGG GCCCTACCTG
951 CATTTCCAC ATGACTTTCT GGAAGCCTCC CAACTATTCT TGCTTTTCCC
1001 AGACAGCTCC CACTCCCATG TCTCTGCTCA TTTAGTCCCG TCTTCCTCAC
1051 CGCCCCAGCA GGGGAACGCT CAAGCCTGGT TGAAATGCTG CCTCTTCAGT
1101 GAAGTCATCC TCTTTCAGCT CTGGCCGCAT TCTGCAGACT TCCTATCTTC
1151 GTGCTGTATG TTTTTTTTTT CCCCCTTCAC TCTAATGGAC TGTTCAGGG
```

Fig. 7

17/25

1201 AAGGGATGGG GGCAGCAGCT GCTTCGGATC CACACTGTAT CTGTGTCATC
1251 CCCACATGGG TCCTCATAAA GGATTATTCA ATGGAGGCAT CCTGACATCT
1301 GTCCATTTAG GCTTCAGTTC CACTCCCAGG AACTTTGCCT GTCCCACGAG
1351 GGAGTATGGG

(SEQ ID NO:7)

IL-18BPd; protein

Length: 161 June 5, 1998 13:40 Type: P Check: 2239 ..

1 MRHNWTPDLS PLWVLLCAH VVTLLVRATP VSQTTTAATA SVRSTKDPCP
51 SQPPVFPAAK QCPALEVTWP EVEVPLNGTL SLSCVACSRF PNFSILYWLG
101 NGSFIEHLPGLWEGSTSRE RGSTGWAEGN LAPHPRSPAL QPQQSTAAGL
151 RLSTGPAAAQ P

(SEQ ID NO:8)

Fig. 7A

18/25

HulL-18BP gene

Length: 7812 July 15, 1998 11:55 Type: N Check: 7058 ..

1 GTCGACGGTA CCCCCGGGAA AGATTTAATA CGACTCACTA TAGGGCGGGA
51 CAGAATTGAT CTGTGAGAGA CTCATCTAGT TCATACCCTA GGTGACCCTG
101 GGGGTGGCAT GGGGGTAGAT TAGAGATCCC AGTCTGGTAT CCTCTGGAGA
151 GTAGGAGTCC CAGGAGCTGA AGGTTTCTGG CCACTGAACT TTGGCTAAAG
201 CAGAGGTGTC ACAGCTGCTC AAGATTCCCT GGTAAAAAG TGAAAGTGAA
251 ATAGAGGGTC GGGGCAGTGC TTTCCCAGAA GGATTGCTCG GCATCCTGCC
301 CTTCCCAGAA GCAGCTCTGG TGCTGAAGAG AGCACTGCCT CCCTGTGTGA
351 CTGGGTGAGT CCATATTCTC TCTTTGGGTC TCAATTTTGC CTTCCCTAAT
401 GAAGGGGTAA GATTGACTA GGTAAGCATC TTACAACCAT TTGTGGTCAT
451 GAGAGCTGGG GTGGGGAAGG ATTGTCACTT GACCCCCCA GCTCTGTTTC
501 TAAGTGCTGA AAGAGCTCCA GGCTATGCTA CGGGAGGAGA AGCCAGCTAC
551 TGAGGAAAAG CCAGCTACTG AGAAAAAGCG GGAGTGGTTT ACCATTCTCC
601 TCCCCACCT TTCACCAGAG AAGAGGACGT TGTCACACAT AAAGAGCCAG
651 GCTCACCAGC TCCTGACGCA TGCATCATGA CCATGAGACA CAACTGGACA
701 CCAGGTAGGC CTTGGGGCTA CGCATGGGCA GGCGGGGTAG GGTGAGGTCT
751 ATGAACAGAA TGGAGCAATG GGCTAACCCG GAGCCTTCAC TCCAAGGCAA
801 ACCACCCAGC GCACCTGGTG CTGTTGCTTT AAGAACCTGG GCAGATATTG
851 TAGCTCTGGC TCCAGTCTAA AGCTTCTCTG TACTCTGTTC AATAAAGGGC
901 TAAGGGGTGG GTGCTGAGGG GTCCCTCTTC CCGCTCTGAT TCCCTGGCTA
951 GAACCCAGAC ATCTCTGGGC TGGAGTTACA TCCTTACCCG GGCAGCCCAC
1001 TCTGTCTCCA GAGCCGCTGA CCTGTAAGTGC TCCTTTCCTC AGACCTCAGC
1051 CCTTTGTGGG TCCTGCTCCT GTGTGCCCCAC GTCGTCACTC TCCTGGTCAG
1101 AGCCACACCT GTCTCGCAGA CCACCACAGC TGCCACTGCC TCAGTTAGAA
1151 GCACAAAGGA CCCCTGCCCC TCCCAGCCCC CAGTGTTCCC AGCAGCTAAG

Fig. 8

19/25

1201 CAGTGTCCAG CATTGGAAGT GACCTGGCCA GAGGTGGAAG TGCCACTGAG
1251 TAAGAAGCAC AGTGGTGGAG GGTGGGCTAT GGGCACAGAG GTTCCCAGGG
1301 TCGGGTTGAC TCCTGAGCGC CAGTCCCCTT CTGCCCATGT ACCACCAGCT
1351 GAGCCAGCTG GGCTGAGCAC GCACCATCTT CCCTCCCCAA CCCAGTGTCA
1401 TGGGTGCAGG CTTGGCGCAG CTCCCAAGAT GCTCCCTATC AAATAGGACA
1451 GAGAACTCAA GACATAAGTA ATGGTCACAG GACCTCCCAG AGCCTTGGTT
1501 GCAGTGGACC CCAAGGCCAG CCCCTCCACC CAGAGCCTGC TGGCCTCTGG
1551 CCATCTCAGA GGAGCAGCAG CCATCCAGCA CTGCCTCTGT CACCTGGGCT
1601 CCCAAGTCAC CGAGGCTGGG CACTAGAAAA GGTCATCCTG AGGAGACAGG
1651 TTCAGAAGAG GATTCATCAC GTGAACCAAG GACCATTCTT CACATTCCCC
1701 GTGTTTAGGG CTAGGGCCTC TCGGAGACAA CTGCACTTCT GTAACGGACG
1751 TTCCACCTA GGTGGTGTGC AGAGCAGTTC TCTAGGTTCC AGATGCATGG
1801 GGACTGGGGG GAGCTGGCAG AGAGGGCACA GCAGAGCAGG GTAGGGGAAG
1851 GGCCTGCTCT TCTGAAGAGC TAACTGCTGC CTGTGTCCCT AGATGGAACG
1901 CTGAGCTTAT CCTGTGTGGC CTGCAGCCGC TTCCCCAACT TCAGCATCCT
1951 CTA CTGGCTG GGCAATGGTT CCTTCATTGA GCACCTCCCA GGCCGACTGT
2001 GGGAGGGGAG CACCAGGTGA GGGTCGCAGC AGCCAGGTGG GTGGGAAGGA
2051 AGCCTTCTGC GGCCTTCTCA TGACCTTTCC TTCCCTTCCG CTCCAGCCGG
2101 GAACGTGGGA GCACAGGTAC GCAGCTGTGC AAGGCCTTGG TGCTGGAGCA
2151 GCTGACCCCT GCCCTGCACA GCACCAACTT CTCCTGTGTG CTCGTGGACC
2201 CTGAACAGGT TGTCCAGCGT CACGTCGTCC TGGCCCAGCT CTGGGTGAGG
2251 AGCCCAAGGA GAGGCCTCCA GGAACAGGAG GAGCTCTGCT TCCATATGTG
2301 GGGAGGAAAG GGTGGGCTCT GCCAGAGCAG CCTGTGAACT AATGCCCAGC
2351 ATTCCTCAAG GTCAGCCAGA CAAAAGGAA CTTAGGTCTT GGGCAGAGGA
2401 GGTGTAGCCT GGGGCAAAGT GATGAGATGT CCCTCCTTTC CTTGGCCTGA
2451 TCCTTGTCTG CCTTCACTTC CCTAGGCTGG GCTGAGGGCA ACCTTGCCCC

Fig. 8A

20/25

2501 CCACCCAAGA AGCCCTGCCC TCCAGCCACA GCAGTCCACA GCAGCAGGGT
2551 TAAGACTCAG CACAGGGCCA GCAGCAGCAC AACCTTGACC AGAGCTTGGG
2601 TCCTACCTGT CTACCTGGAG TGAACAGTCC CTGACTGCCT GTAGGCTGCG
2651 TGGATGCGCA ACACACCCCC TCCTTCTCTG CTTTGGGTCC CTTCTCTCAC
2701 CAAATTCAAA CTCCATTCCC ACCTACCTAG AAAATCACAG CCTCCTTATA
2751 ATGCCTCCTC CTCCTGCCAT TCTCTCTCCA CCTATCCATT AGCCTTCCTA
2801 ACGTCCTACT CCTCACACTG CTCTACTGCT CAGAAACCAC CAAGACTGTT
2851 GATGCCTTAG CTTTGCACTC CAGGGCCCTA CCTGCATTTC CCACATGACT
2901 TTCTGGAAGC CTCCCAACTA TTCTTGCTTT TCCCAGACAG CTCCCACTCC
2951 CATGTCTCTG CTCATTTAGT CCCGTCTTCC TCACCGCCCC AGCAGGGGAA
3001 CGCTCAAGCC TGGTTGAAAT GCTGCCTCTT CAGTGAAGTC ATCCTCTTTC
3051 AGCTCTGGCC GCATTCTGCA GACTTCCTAT CTTCGTGCTG TATGTTTTTT
3101 TTTTCCCCCT TCACTCTAAT GGACTGTTCC AGGGAAGGGA TGGGGGCAGC
3151 AGCTGCTTCG GATCCACACT GTATCTGTGT CATCCCCACA TGGGTCTCA
3201 TAAAGGATTA TTCAATGGAG GCATCCTGAC ATCTGTTTCAT TTAGGCTTCA
3251 GTTCCACTCC CAGGAACTTT GCCTGTCCCA CGAGGGAGTA TGGGAGAGAT
3301 GGACTGCCAC ACAGAAGCTG AAGACAACAC CTGCTTCAGG GGAACACAGG
3351 CGCTTGAAAA AGAAAAGAGA GAACAGCCCA TAATGCTCCC CGGGAGCAGA
3401 GGCCACTAAT GGAGAGTGGG AAGAGCCTGG AAAGATGTGG CCTCAGGAAA
3451 AGGGATGAGA GAAAGGAGGT GGTATGGAAG ACTCAGCAGG AACAAGGTAG
3501 GCTTCAAAGA GCCTATATTC CTCTTTTTTCC CACACCGATC AAGTCAACTC
3551 AGTACTCAGC GGAGAAAAAT AGACTTTATT TACAAGTAAT AACATTTAGA
3601 AAAGATCCAT CCCC GGCCCT TAAAAACCTT CCCATCACTC CAAATCCCAC
3651 CCCAGTGCAA GTCTGGGGAA GGTAGGGTGT GAGCTGCTGC TGAAGGCTGT
3701 CCCCCAACCC CACTCCTGAG ACACAGGGCC CATCCGTCCT GGGAAAGAGC
3751 ATCCTCTGGC AGGTGCTCCC ACCAGGTCAG ACCCAGTCCT GGA CTCAAG

Fig. 8B

21/25

3801 AGTGAGGGCC CCTGCTGGGC CCAGCCACCA GGACAGCAGG AACCAGGGCC
3851 TACTCCTCTT ATGGTCCCTT CTAGATCCAG AGGCTAAGAG GAAGACTGGC
3901 CAGGCCCAAG GACCCAGCCA TCAAAACCAG CCTCAAATCT GGTGTGTATG
3951 GAGAAGTGAC TTTGCTTTAA GAAAAAAGGA GGCAAGGTAG GGAGAGCGCC
4001 CACACTGTCC ATGCTCCAGG CCCCCTGGGC CAGCTCCGAG AAGGCGCCAG
4051 TGAAGGACCA GGGACCAGGC CAGGGTGCGG GCAGGCATCA CTGTCTCTAG
4101 GGGTTTGGCT ACTGTTGGCC TGGGAGCTGA GAGAAGGCAC TGAGAGGGAC
4151 AGTAGGCGGA GGACCAGGTG ACGGCAGCAT CGGGGACACA GGTGGGGCCA
4201 CTCACTGGTA CTGGCCCTTT AGTGCTTTGC CTGAAAGAGA CACAGTCACA
4251 TGGCCAGATG AGAACTTGCG AACTAGCCT GCACCCACTG GCTGGGAAGA
4301 TCTCTTCCTG CTCCCACGCC CCTGTCTGGA TCCCCTCCCT TGTGAGCCCC
4351 AGGGTTATCA GTTGCTGGCT GTGCCTGAGC AGCTCTGGGT GCTCTCCATG
4401 AGAATGGGGC CATCTGTCTT CTCTCCTTGG AGAGGAGCTA CCAGGACAGG
4451 GACACCTCTT ACCCCACACC CTCCAGCAGC CTGGCGTGGC CCCATCTTGG
4501 ATGCTACTTG GTGGGGCGGT CTGGGGGGTG CCCATGCTCT CATCGGGTTT
4551 CCCTCCCCCA TCCTGCCAGT GCCTCTACCT TGCCCTTGGC TCGAGGGGTG
4601 GCACCAATGG CGGCAGCAGT GGCGGCGCTG GCTGTGGTGG TGGCAATGCG
4651 CGGAGAACGG CGGGTTCCAC TGCAGTGTT GGGGGAAGCC TTGGACAGGG
4701 CCTTCTTTGA GGCTCCCCGC CGCAGAAGGC TGTTCCCTAG CTTCTTGGGT
4751 GTGTTGAGGA TGCTGAAGGC CATCGACTGG CGCCGGTCAG CCTGCAAGGA
4801 AGGGCTGTCA GACCGGGAGA CCAATGCTG CCTTCCCAGG CCAGCGTGCT
4851 GTGCCACGCT GTACCAGCAA GGTCCCGCCA GGGCGTCGCT TCATCCCCCT
4901 TCAGCCCCAG CCTCACCTGT TTAGTAGAAG CTGGAGCTGC TTTCTTCTGG
4951 GCCTCAGTAG TGCTCTGTTT GCGCCCTTCA TGTCGGTCTC GGGGAGTCAT
5001 GGGGCGTGGG AAACAGCTGG TGGCCTTCTT AGACTATGGA GAAGAGGACA
5051 GTTAGGCAGA CAGTAGCAAG AGGAGTCACA TCTGAAGCCA GGTGTCTTGT

Fig. 8C

22/25

5101 CCTCTCAGAG CTGAGTGGAC CTTGTAAGTC AACGTGCAAC CTGCTCCCCCT
5151 TCCCAACTCT GGGCCAGATC CTTCCCTTCC CAACAGTTCC CATCCATGGG
5201 TCAGGCCCTT GGAGAGAGGG AAAGAGAGGG GGAAGTGAGG GAAGGAGAGA
5251 GAAGGCTCCC TTTAGTCCTT GGTGAGCTGG GCCTGACCTG AGCACAGTGC
5301 TGGAGTAACA CCCAGGAGCC ACCGCGCCTA CCTCAGGAGT TCCAGGGCCC
5351 TGGTGGGGCT CTAGGGAGAC CCGTTTGCGC TGCTGCCGGG TGGTGATGCC
5401 AGTGCCCTCG GCTATCTGGA TTGGCTGCAT GCTGGCTCGG CGCAGGGTCT
5451 CTTGGGGGTC TCCAGTTTTT ATCTCCTCAT CTGTGATGGT GCCCAGGCTC
5501 AGGGAAGGCT GCATGGGTGG AAGAGGTGGT CAGTGGACCA TAGCTGTATG
5551 GAGATGGAGG AGGACCTGGG GCTGTTCCAG AACTCTACAC TCGCCCGACA
5601 CTTATGGTCG GGACCCTTCC TGCCTACGAG GTAGAAAGAC ACAAGCCTCC
5651 TTTCTGTTC TGCTTTCTAC CTAAGCCCTG GGCAAATGGC ACAAGCAGTG
5701 CAGTCCTGAC CAGATTCTC TCTGAGCTCC TGCCTACCCC CAGGGACTTC
5751 ACCCCTGAGT GCCCTCCAGC TGTCTGTTCC ACCTGGAACA TGAGAAGGTC
5801 ACCCCTTCCC CTCTTCGGCC AGTCAGTGAT CCAGGGCCCT AGTGCTCAGG
5851 CTAGATCAGC AGGTGGGATT CCAAGGAAGG GCAGGGATGG GAGGCCCTGC
5901 ACAGTGACCC CAGGCCTCAC CCTGGACTCC AGGGATAGCA GGTCTTCAGA
5951 TGTGGGGGGC AACTCGATT GCGCTGCTGC AGCTCTGCAA TGCGGTTCCA
6001 GTCATCCAGC TGCTCAGGCT CATCCTGGCA AGTGCCCATG TAGAAGCTGT
6051 TCCTTCCTGT GGAAGGCAGG GAAGTGGGAA CAAATGAGCC TGGAGTCGGC
6101 AGGTCACCTC CTGGCCCTGG CATCTTGCCA GCCTTTGCTG CCACCTACCC
6151 CATAAACTTG AAGCCCGGCA CACCAGTCTG ATTCAGTGCC GCAGGTGCAG
6201 GAGTACGGCA CACAGACTAT TTCTATCCTA GGGGCTTGCT CACCACCTTC
6251 TCCCTGGAGA GGGCAGAAGA GGTCACACGC AGAGACTGCT ACTACATCTT
6301 ATTCACCTGC CAAGGCTTGG TGGCCAACAC CCAGAGGAAC AAATTAAGGA
6351 CCGGGAATTA ATTCCCAGGG GCTCCCTGGT GCCCAAAGGA CAAGAGCTTC

Fig. 8D

23/25

6401 CAAGAAGAGT CTGGCCAGCC TGGCCTTTCC AGCAGCCCAT CACCGCCTGA
6451 GAAGGGCATG GAGGACTCCC CACAGCTAAG TGTCACAATT GTGCTGGGAA
6501 TCCCGGGCCC TTA ACTCTGG CTAAGAGTGC CCCAACACA GCCAGCCCCT
6551 AGATGGGCAG GTAAGGAAGG CCCTGAGGCT GCAGGAAGGA GGGGCAGGTG
6601 GAGCTGGATG GTAGCAAGGA GGCCAGCCTT GGATTTTAA AAAGCTTTCC
6651 TCTTTTCCCT GTGCCACGAT CCACCTTCCA GTCTAATTTT GGGGTATAGT
6701 AAGTCCCTGT AGTCCCCTCA CCTGGAGGGG CCCCCTGGA CACCCCGGCC
6751 TGGGAACGAC GAGCAGAACT GCGAGTGGTG GGGCGGTAGC CAGGCAAGCT
6801 GAGCAGGGCT GAGTTGCCAT AATCGGGAGA ACCCAGGCGA GCTAGAGACT
6851 GAGTAGAGGA GGTGGCTCGC AGGCTAGCCT GGAAGCAGG AGCAGACCGC
6901 GTGCTGTAGA ACGATGAGTT GGCGCTGTCT GGCTCTTCCA CATCTAGCTT
6951 CTGGAAGACA GAGTGAATCT GTTGCAGTGT ACAGTCCCTG GCACTGTACA
7001 GAAGCTTCCC ATTCCCTTCC GAAGCCCTCA GATCCCACGG CACATCCATG
7051 TATTCCTAAC TGCTTTGCAA AGGTCCTTAA AGTGTGTGTC TGCAAGAAAT
7101 GGGCCTTGTC GACAGAAGCC CTCACAAGGT GGTGCTGATG TTGTCAAGAC
7151 TCTTCTACGC ATTTTTTTCA TGGAGTCTAT TCATAATGCT TTGAGGTAGG
7201 GAATGCAGAG TGTTTATCGG CCCATTTTGG AGATGAAGTG CAAAGAAATA
7251 AAGTGA CTAG CCCCAAATCA CACTGCTAGG AAGTATCAGA GCTGGGGCTA
7301 GGCCCCATGT CTCCTGACTA GTCAGGCTCA TCCCACAGCC TCTGCTGTCC
7351 CTCAGTCCAA ACTTCCAGGG CCCTTACCAT GTTCCAGAAC TTCCCCAAC
7401 TTCTTGGTAG CAGGGGGCAC CCTAAACACA CAGGTCCCCC CTGCTGTACC
7451 AGGGGCCCCC TCTCCCCTCC TCCCAAACCT CCCCTTCAAG ATGTGGAAAC
7501 AAAGGCAAGG GCCTGCAGCC TGTCAGGCAG TCCACTGGGC AGCAACAATG
7551 CCTCTCAGCT GCATGGGGCA TGCTGGGAGG CACAGGATGG GCTGCAGCTT
7601 CGCCACGTTT TCTCCCTTCA CCCTGCACAG GCTCAGTGCT ACGCATGGAG
7651 AGAATGCTAG CCTTAGTCAG GAGGCAGGGA TCTAATCCTA GCCCTGCCTT

Fig. 8E

24/25

7701 TTTCTTCAGA AGTGCCCTTA ACCAAGTCAC TGCCCTTTTT AAGACCTCTC
7751 AGCTTTCCCA CTGTAAACATG GACTGGCTGC TCATCCCTCC CTGCTCCTGA
7801 CTGAGTGCCC AG

(SEQ ID NO:9)

Fig. 8F




Fig. 9 A-D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IL 98/00379

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EMBL Database entry 0 00923, accession number 0 00923, Merozite Surface Protein 1 (fragment), 01/07/97 XP002087999 see abstract	1
A	EMBL Database entry 0 00919, accession number 0 00919, Merozite Surface Protein 1 (fragment), 01/07/97 XP002088000 see abstract	1

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

15 December 1998

Date of mailing of the international search report

29/01/1999

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Deffner, C-A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 98/00379

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL Database entry HSZZ16951, accession number AA311795, Adams M.D. et al., EST182531 Jurkat T-cells VI Homo sapiens cDNA 5'end similar tp Hypothetical protein C9, 18/04/97 XP002088001 see abstract ---	12
X	EMBL Database entry HSA10059, accession number AA010059, Hillier L. et al., zell6a02.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone, 02/08/96 XP002088002 see abstract ---	12
X	EMBL Database entry HZZ03012, accession number g1950205, Adams M.D. et al., EST182531 Jurkat T-cells V Homo sapiens cDNA 5'end 18/04/97 XP002088003 see abstract ---	12
X	EMBL Database entry HSNUMAMR, accession number g35118, Yang C.H. et al., NuMA: an unusually long coiled-coil related protein in the mammalian nucleus, 27/03/92 XP002088004 see abstract ---	12
X	EMBL Database entry HSNUMAT3G, accession number g296118, Tang T.K. et al., Nuclear protein of Bovine esophageal epithelium, 31/03/93 XP002088005 see abstract ---	12
A	EMBL Database entry Q98222, accession number Q98222, Senkevich T.G. et al., Viridae; DS-DNA enveloped viruses; poxyviridae; chordopoxvirinae, Molluscipoxiviruses 01/02/1997 XP002088006 see abstract ---	3
A	EMBL Database entry Q98221, accession number Q98221, Senkevich T.G. et al., Viridae; DS-DNA enveloped viruses; poxyviridae; chordopoxvirinae, Molluscipoxiviruses 01/02/1997 XP002088007 see abstract --- -/--	3

INTERNATIONAL SEARCH REPORT

Int tional Application No

PCT/IL 98/00379

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EMBL Database entry Q17343, accession number Q17343, Otsuka A.J. et al., UNC-44 Ankyrins, 01/11/1996 XP002088008 see abstract</p> <p>-----</p>	3